[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 343
1. Hanagiri T, Oka S, Takenaka S, Baba T, Yasuda M, Ono K, So T, Uramoto H, Takenoyama M, Yasumoto K: Results of surgical resection for patients with large cell carcinoma of the lung. Int J Surg; 2010;8(5):391-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgical resection for patients with large cell carcinoma of the lung.
  • PURPOSE: The clinical features of large cell carcinoma (LCC) of the lung have remained unclear due to the low incidence of the disease.
  • The mean smoking pack-year index was 49.9 in the patients with LCC, 27.1 in 625 patients with adenocarcinoma, and 52.5 in 266 patients with squamous cell carcinoma, and this was significantly higher in the patients with LCC than in those with adenocarcinoma.
  • The mean tumor diameter was 38 mm for LCC, 28 mm for adenocarcinoma, and 39 mm for squamous cell carcinoma.
  • The pathological stage was IA in 11 patients, IB in 11, II in 12, IIIA in 16, IIIB in 5, and IV in 2.
  • The post-operative 5-year survival rate was 60.5% for LCC, 64.3% for large cell neuroendocrine carcinoma, 67.0% for adenocarcinoma, and 50.1% for squamous cell carcinoma.
  • CONCLUSION: The tumor diameter was significantly larger for LCC than for adenocarcinoma at the time of diagnosis.
  • The proportion of smokers and the smoking pack-year index in patients with LCC were significantly higher than those of adenocarcinoma.
  • The surgical results were similar between LCC and other non-small cell lung carcinomas.
  • [MeSH-major] Carcinoma, Large Cell / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20547250.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Hartsell WF, Scott CB, Dundas GS, Mohiuddin M, Meredith RF, Rubin P, Weigensberg IJ: Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03. Am J Clin Oncol; 2007 Aug;30(4):368-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
  • PURPOSE: To identify factors that are predictive of satisfactory acute and long-term pulmonary tolerance of definitive irradiation and, conversely, factors that are predictive of excessive impairment of pulmonary functions.
  • Eligible patients had surgically unresectable or medically inoperable stage II or III non-small cell lung cancer.
  • A quantitative nuclear medicine perfusion study was correlated to the radiation therapy portals to assess the proportion of lung irradiated.
  • Squamous cell carcinoma was the predominant histology and 93% of the patients had AJCC stage III disease.
  • Grade >or=2 acute lung toxicity was seen in 18% of patients; patients least likely to develop lung toxicity are those with undetectable levels of IL-6 at 10 Gy and diffusing capacity of the lung for carbon monoxide percent (DLCO%) >54.
  • Grade >or=2 late lung toxicity was seen in 30% of patients.
  • Karnofsky performance status was the only pretreatment factor predictive of late lung toxicity.
  • The proportion of lung within the irradiated field, BDI indices, physician-assessed baseline dyspnea, and baseline PFT were not predictive of pulmonary toxicity.
  • Using grade >or=2 toxicity as an event, age >60 years, gender, and a surfactant level <797 at 20 Gy were predictive of late lung toxicity.
  • CONCLUSIONS: Elevated levels of serum IL-6 after 10 Gy of lung irradiation appear to predict grade >or=2 acute lung toxicity, and high serum levels of surfactant apoproteins at 20 Gy correlated with grade >or=2 late pulmonary toxicity.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / radiotherapy. Interleukin-6 / blood. Lung Neoplasms / radiotherapy. Radiation Injuries / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / radiotherapy. Carcinoma, Large Cell / blood. Carcinoma, Large Cell / radiotherapy. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / radiotherapy. Female. Humans. Lung / radiation effects. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Radiotherapy Dosage. Respiratory Function Tests. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762437.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-6
  •  go-up   go-down


3. Ceribelli A, Pino MS, Gelibter AJ, Milella M, Cecere FL, Caterino M, Facciolo F, Mirri A, Cognetti F: Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel. Cancer; 2007 Feb 15;109(4):727-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel.
  • BACKGROUND: Improving results in nonsmall-cell lung cancer (NSCLC) will require the development of new drugs and strategies to combine available agents.
  • On the basis of data indicating the activity of docetaxel as second-line therapy, a Phase II study was conducted to evaluate the efficacy and toxicity of the sequential combination of chemotherapy consisting of cisplatin (P) and gemcitabine (G) followed by docetaxel (DOC) in patients with advanced NSCLC.
  • METHODS: Patients with 1997 TNM stage IIIB (pleural effusion)/stage IV NSCLC, performance status (PS) of 0-1, and normal organ function were eligible.
  • RESULTS: Fifty-two eligible patients were enrolled (M/F, 39/13; stage IIIB/IV, 8/44; PS 0, 73%, PS 1, 27%; median age, 58 years; range, 36-73).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17238182.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Rossi D, Dennetta D, Ugolini M, Catalano V, Alessandroni P, Giordani P, Baldelli AM, Casadei V, Graziano F, Luzi Fedeli S: Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial. Target Oncol; 2010 Dec;5(4):231-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial.
  • Efficacy of this drug was documented in the BR.21 trial showing that adenocarcinoma, female gender, Asian ethnicity and never-smoker status are predictive of clinical response to erlotinib.
  • The trial included 31 patients with pretreated stage IIIB (2) and IV (29) non-small cell lung cancer (NSCLC).
  • Even though this trial does not allow us to draw a definitive conclusion about the role of a particular clinical characteristic predictive of response, the "clinical benefit" was documented especially in females, in patients with adenocarcinoma histology and skin rash, confirming previous retrospective data.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Aged. Aged, 80 and over. Erlotinib Hydrochloride. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Sex Factors. Smoking / adverse effects. Tumor Stem Cell Assay

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3543-51 [18506025.001]
  • [Cites] Lancet. 2008 Nov 22;372(9652):1809-18 [19027483.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3159-67 [10880430.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2350-7 [18467727.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1589-97 [15117980.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] N Engl J Med. 1999 Dec 30;341(27):2061-7 [10615079.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2354-62 [10856094.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4405-11 [16983108.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 5;95(5):362-72 [12618501.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):190-6 [15625373.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1383-9 [12663731.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Lung Cancer. 2008 Oct;62(1):78-84 [18423781.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 6;91(1):66-72 [9890172.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4663-9 [17925563.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Chest. 2005 Aug;128(2):947-57 [16100191.001]
  • (PMID = 20890670.001).
  • [ISSN] 1776-260X
  • [Journal-full-title] Targeted oncology
  • [ISO-abbreviation] Target Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Adenocarcinoma of lung
  •  go-up   go-down


5. Skúladóttir R, Oskarsdóttir GN, Isaksson HJ, Jónsson S, Thorsteinsson H, Gudbjartsson T: [Postoperative complications following lobectomy for lung cancer in Iceland during 1999-2008]. Laeknabladid; 2010 Apr;96(4):243-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative complications following lobectomy for lung cancer in Iceland during 1999-2008].
  • OBJECTIVE: Non small cell lung cancer (NSCLC) is the second most common cancer in Iceland.
  • Data on indications, histology, TNM-stage and complications were analysed, and logistic regression used to assess outcome predictors.
  • Adenocarcinoma (62%) and squamous cell carcinoma (29%) were the most frequent histological types.
  • Operative staging showed that 59.6% of cases were stage I, 17.8% were stage II, 7% were stage IIIA and 14.6% were stage IIIB or IV.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Outcome and Process Assessment (Health Care). Pneumonectomy / adverse effects. Postoperative Complications / etiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20339163.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


6. Desai SP, El-Rayes BF, Ben-Josef E, Greenson JK, Knol JA, Huang EH, Griffith KA, Philip PA, McGinn CJ, Zalupski MM: A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer. Am J Clin Oncol; 2007 Aug;30(4):340-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer.
  • METHODS: Patients with adenocarcinoma of the rectum stage >or=T3 or >or=N1 were treated with capecitabine 1330 mg/m per day in 2 divided doses days 1 to 42 and 50.4 Gy of RT in 28 1.8-Gy fractions.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Capecitabine. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Preoperative Care. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762432.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA091975
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Heller G, Fong KM, Girard L, Seidl S, End-Pfützenreuter A, Lang G, Gazdar AF, Minna JD, Zielinski CC, Zöchbauer-Müller S: Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene; 2006 Feb 9;25(6):959-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas.
  • TSLC1 (tumor suppressor in lung cancer-1, IGSF4) encodes a member of the immunoglobulin superfamily molecules, which is involved in cell-cell adhesion.
  • TSLC1 is connected to the actin cytoskeleton by DAL-1 (differentially expressed in adenocarcinoma of the lung-1, EPB41L3) and it directly associates with MPP3, one of the human homologues of a Drosophila tumor suppressor gene, Discs large.
  • Recent data suggest that aberrant promoter methylation is important for TSLC1 inactivation in lung carcinomas.
  • Thus, we investigated the expression and methylation patterns of these genes in lung cancer cell lines, primary lung carcinomas and nonmalignant lung tissue samples.
  • By reverse transcription-polymerase chain reaction, loss of TSLC1 expression was observed in seven of 16 (44%) non-small-cell lung cancer (NSCLC) cell lines and in one of 11 (9%) small-cell lung cancer (SCLC) cell lines, while loss of DAL-1 expression was seen in 14 of 16 (87%) NSCLC cell lines and in four of 11 (36%) SCLC cell lines.
  • In tumors of NSCLC patients with stage II-III disease, DAL-1 methylation was seen at a statistically significant higher frequency compared to tumors of patients with stage I disease.
  • A significant correlation between loss of expression and methylation of the genes in lung cancer cell lines was found.
  • The majority of nonmalignant lung tissue samples was not TSLC1 or DAL-1 methylated.
  • Re-expression of TSLC1 and DAL-1 was seen after treatment of lung cancer cell lines with 5-aza-2'-deoxycytidine.
  • [MeSH-major] Carcinoma / genetics. DNA Methylation. Gene Expression Regulation, Neoplastic. Immunoglobulins / genetics. Lung Neoplasms / genetics. Membrane Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Antimetabolites, Antineoplastic / pharmacology. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / pathology. Cell Adhesion Molecules. Humans. Microfilament Proteins. Nuclear Proteins / genetics. Oligonucleotide Array Sequence Analysis. Transcription Factors / genetics. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16205641.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 70907
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / CADM1 protein, human; 0 / Cell Adhesion Molecules; 0 / DLG3 protein, human; 0 / EPB41L3 protein, human; 0 / Immunoglobulins; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


8. Sasaki H, Hikosaka Y, Okuda K, Kawano O, Yukiue H, Yano M, Fujii Y: CHRNA5 gene D398N polymorphism in Japanese lung adenocarcinoma. J Surg Res; 2010 Jul;162(1):75-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CHRNA5 gene D398N polymorphism in Japanese lung adenocarcinoma.
  • BACKGROUND: Recently, to identify genetic factors that modify lung cancer risk, CHRNA5 non-synonymous variant amino acid position 398 (D398N) was identified.
  • MATERIALS AND METHODS: We have investigated CHRNA5 gene polymorphism status in 302 surgically treated lung adenocarcinoma cases from Nagoya City University Hospital.
  • The polymorphism statuses were not correlated with gender (women; 2.1% versus men; 3.7%, P = 0.5119), smoking status (never smoker; 2.0% versus smoker; 4.0%, P = 0.3339), pathological stages (stage I; 2.6% versus stage II-IV; 3.8%, P = 0.7246), and EGFR mutation status of the lung adenocarcinomas (mutation; 2.3% versus wild type; 3.7%, P = 0.7373).
  • CONCLUSION: Although CHRNA5 polymorphism is rare from Japanese lung cancer, polymorphism status might be correlated with shorter survival.
  • [MeSH-major] Adenocarcinoma / genetics. Lung Neoplasms / genetics. Nerve Tissue Proteins / genetics. Receptors, Nicotinic / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010. Published by Elsevier Inc.
  • (PMID = 19577767.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CHRNA5 protein, human; 0 / Nerve Tissue Proteins; 0 / Receptors, Nicotinic
  •  go-up   go-down


9. Venuta F, Ciccone AM, Anile M, Ibrahim M, De Giacomo T, Coloni GF, Rendina EA: Reconstruction of the pulmonary artery for lung cancer: long-term results. J Thorac Cardiovasc Surg; 2009 Nov;138(5):1185-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reconstruction of the pulmonary artery for lung cancer: long-term results.
  • OBJECTIVE: Reconstruction of the pulmonary artery in association with lung resection is technically feasible with low morbidity and mortality.
  • To assess long-term outcome, we report our 20-year experience.
  • METHODS: Between 1989 and 2008, we performed pulmonary artery reconstruction in 105 patients with non-small cell lung cancer (tangential resections not included).
  • Fifteen patients had stage IB disease, 37 stage II, 31 IIIA, and 22 IIIB.
  • Sixty-one patients had epidermoid carcinoma, and 38 adenocarcinoma.
  • Five- and 10-year survivals for stages I and II versus stage III were, respectively, 60% versus 28% and 25% versus 12%.
  • Multivariate analysis yielded induction therapy, N2 status, adenocarcinoma, and isolated pulmonary artery reconstruction as negative prognostic factors.
  • CONCLUSIONS: Pulmonary artery reconstruction is safe, with excellent long-term survival.
  • Our results support this technique as an effective option for patients with lung cancer.
  • [MeSH-major] Lung Neoplasms / pathology. Lung Neoplasms / surgery. Pulmonary Artery / pathology. Pulmonary Artery / surgery. Reconstructive Surgical Procedures / methods. Vascular Surgical Procedures / methods


10. Ramnath N, Sommers E, Robinson L, Nwogu C, Sharma A, Cantor A, Bepler G: Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer. Chest; 2005 Nov;128(5):3467-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer.
  • OBJECTIVE: We assessed the efficacy of a non-platinum-containing doublet chemotherapy of gemcitabine and vinorelbine as induction therapy prior to surgical resection in patients with stage IB-IIIA and selected stage IIIB non-small cell lung cancer (NSCLC).
  • RESULTS: Between January 2000 and March 2004, 27 patients with stage IB NSCLC, 15 patients with stage II NSCLC, and 20 patients with stage III NSCLC were entered.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304301.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


11. Strand TE, Rostad H, Møller B, Norstein J: Survival after resection for primary lung cancer: a population based study of 3211 resected patients. Thorax; 2006 Aug;61(8):710-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after resection for primary lung cancer: a population based study of 3211 resected patients.
  • BACKGROUND: Very few population based results have been presented for survival after resection for lung cancer.
  • The purpose of this study was to present long term survival after resection and to quantify prognostic factors for survival.
  • METHODS: All lung cancer patients diagnosed in Norway in 1993-2002 were reported to the Cancer Registry of Norway (n = 19 582).
  • RESULTS: Five year relative survival in the period 1993-9 was 46.4% (n = 2144): 58.4% for stage I disease (n = 1375), 28.4% for stage II (n = 532), 15.1% for IIIa (n = 133), 24.1% for IIIb (n = 63), and 21.1% for stage IV disease (n = 41).
  • The high survival in stage IIIb and IV was due to the contribution of multiple tumours.
  • Cox regression analysis identified male sex, higher age, procedures other than upper and middle lobectomy, histologies such as adenocarcinoma and large cell carcinoma, surgery on the right side, infiltration of resection margins, and larger tumour size as non-favourable prognostic factors.
  • CONCLUSIONS: Survival was favourable for resected patients in a population based group including subgroups such as elderly patients, those with advanced stage, small cell lung cancer, tumours with nodal invasion, and patients with multiple tumours.
  • These results question the validity of the current TNM system for lung cancer with regard to tumour size and categorization of multiple tumours.
  • [MeSH-major] Lung Neoplasms / mortality. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Dec 1;86(11):2229-37 [10590362.001]
  • [Cites] N Engl J Med. 2001 Jul 19;345(3):181-8 [11463014.001]
  • [Cites] Ann Thorac Surg. 2001 Oct;72(4):1155-9 [11603429.001]
  • [Cites] Lung Cancer. 2001 Nov;34(2):169-75 [11679175.001]
  • [Cites] Surgery. 2002 Jan;131(1):6-15 [11812957.001]
  • [Cites] Tidsskr Nor Laegeforen. 2003 May 29;123(11):1525-6 [12822014.001]
  • [Cites] Lung Cancer. 2003 Jul;41(1):57-64 [12826313.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):289-300 [12973707.001]
  • [Cites] Ir Med J. 2003 Sep;96(8):237-40 [14653375.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v61-118 [14684501.001]
  • [Cites] Cancer Causes Control. 2004 Feb;15(1):27-33 [14970732.001]
  • [Cites] Ann Thorac Surg. 2004 Jun;77(6):1926-30; discussion 1931 [15172237.001]
  • [Cites] Ann Thorac Surg. 2004 Sep;78(3):999-1002; discussion 1002-3 [15337036.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Oct;26(4):782-6 [15450573.001]
  • [Cites] Ann Thorac Surg. 1982 May;33(5):459-63 [7082083.001]
  • [Cites] Ann Thorac Surg. 1985 Jul;40(1):60-4 [4015245.001]
  • [Cites] Ann Thorac Surg. 1988 Apr;45(4):380-3 [3355279.001]
  • [Cites] Eur J Cardiothorac Surg. 1991;5(3):132-6 [1851020.001]
  • [Cites] Chest. 1991 Aug;100(2):422-8 [1650679.001]
  • [Cites] World Health Stat Q. 1992;45(1):117-64 [1413853.001]
  • [Cites] Eur J Cancer. 1993;29A(13):1809-13 [8260230.001]
  • [Cites] Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3 [7677489.001]
  • [Cites] Thorax. 1996 Dec;51(12):1266-9 [8994527.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Lung Cancer. 2004 Dec;46(3):325-31 [15541817.001]
  • [Cites] Lung Cancer. 2005 Feb;47(2):173-81 [15639716.001]
  • [Cites] Eur J Cardiothorac Surg. 2005 Feb;27(2):325-8 [15691690.001]
  • [Cites] Lung Cancer. 2005 Nov;50(2):227-34 [16061304.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 May;29(5):824-8 [16520052.001]
  • [CommentIn] Thorax. 2006 Aug;61(8):649-50 [16877689.001]
  • (PMID = 16601091.001).
  • [ISSN] 0040-6376
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2104691
  •  go-up   go-down


12. Wang XY, Yao Z, Li Y, Liu T, Zheng HY, Zhu CZ, Sun CY, Wang AX, Zhao M, Wu XY: Expression and significance of Survivin mRNA in lung cancer tissue microarray detected by FISH. Chin Med Sci J; 2005 Sep;20(3):214-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and significance of Survivin mRNA in lung cancer tissue microarray detected by FISH.
  • OBJECTIVE: To investigate the expression of Survivin mRNA in lung cancer tissue microarray (TMA) by fluorescence in situ hybridization (FISH) method, and determine the role and significance of it in lung cancer genesis and progress.
  • Fifty-four cases of lung cancer and 10 cases of normal lung tissue were examined.
  • RESULTS: Survivin mRNA was expressed in 66.7% (36/54) of lung cancer; the positive ratio of lung cancer was significantly higher than that of normal lung tissue (0/10; chi2 = 15.238, P < 0.05).
  • The positive ratio of Survivin mRNA was significantly higher in stage III-IV(12/13, 92.3%) than stage I - II (24/41, 58.5%; chi2 = 5.066, P < 0.05).
  • CONCLUSION: Survivin mRNA highly expresses in lung cancer, which is related to the progress and malignant behavior.
  • Survivin may play a promoting role in lung cancer genesis and progress and provide a basis for estimating prognosis and treatment.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16261898.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


13. Sandler A, Herbst R: Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res; 2006 Jul 15;12(14 Pt 2):4421s-4425s
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Additionally, both agents have shown benefit in patients with previously treated non-small cell lung cancer (NSCLC).
  • A phase I/II study in two centers examined combined erlotinib and bevacizumab treatment in patients with nonsquamous stage IIIB/IV NSCLC with one or more prior chemotherapy.
  • In phase I, 150 mg/d erlotinib orally plus 15 mg/kg bevacizumab i.v. every 21 days was established as the phase II dose.
  • A total of 40 patients were enrolled and treated in this study (34 patients at phase II dose): 21 were female, 30 had adenocarcinoma histology, 9 were never smokers, and 22 had two or more prior regimens.
  • The median overall survival for the 34 patients treated at the phase II dose was 12.6 months, with progression-free survival of 6.2 months.
  • A randomized phase II trial has been completed, and a phase III trial is ongoing.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Epidermal Growth Factor / antagonists & inhibitors. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Drug Synergism. Erlotinib Hydrochloride. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16857821.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Quinazolines; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; 62229-50-9 / Epidermal Growth Factor; DA87705X9K / Erlotinib Hydrochloride
  • [Number-of-references] 22
  •  go-up   go-down


14. Nyman J, Friesland S, Hallqvist A, Seke M, Bergström S, Thaning L, Lödén B, Sederholm C, Wagenius G: How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group. Lung Cancer; 2009 Jul;65(1):62-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group.
  • BACKGROUND: A combination of chemotherapy and radiotherapy is the treatment base for locally advanced non-small cell lung cancer (NSCLC).
  • Attempts to improve the loco-regional control were made in three separate phase II studies in Swedish University Hospitals, where accelerated radiotherapy or concurrent daily or weekly chemotherapy with conventional radiotherapy were tested.
  • Comparatively good results from these studies lead to this national randomized phase II study, the RAKET-study, where the different concepts were investigated on a wider basis for further phase III studies.
  • METHODS: Inoperable stage III non-small cell lung cancer patients in good performance status (PS<2) were equally randomized to either of three arms in eight institutions.
  • Thirty-four percent had stage IIIa and 66% IIIb.
  • HISTOLOGY: adenocarcinoma 48%, squamous cell carcinoma 32% and 20% non-small cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19081652.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


15. Hashimoto H, Ozeki Y, Sato M, Obara K, Matsutani N, Nakagishi Y, Ogata T, Maehara T: Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer; 2006 Apr 1;106(7):1595-601
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung.
  • However, this association has not been clarified for nonsmall cell lung carcinoma.
  • In the current study, the authors investigated the clinicopathologic significance of TS mRNA levels and the correlation with cellular proliferation in patients with lung adenocarcinoma.
  • METHODS: The expression levels of TS mRNA were measured in 47 lung adenocarcinoma tissues using the Taq-Man real-time reverse transcriptase-polymerase chain reaction (RT-PCR) method and examined the clinicopathologic significance of TS expression.
  • RESULTS: A positive correlation was observed between the expression levels of TS mRNA and stage of disease, lymph node metastasis, or tumor differentiation (P = .015).
  • CONCLUSIONS: The results of the current study demonstrated that TS may be associated with stage of disease, lymph node metastasis, tumor differentiation, prognosis, and tumor cell proliferation.
  • These results suggest that the expression levels of TS mRNA may be useful for predicting the malignant potential in patients with lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Carcinoma, Non-Small-Cell Lung / enzymology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / enzymology. Lung Neoplasms / pathology. Thymidylate Synthase / biosynthesis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16489621.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


16. Pajares MJ, Zudaire I, Lozano MD, Agorreta J, Bastarrika G, Torre W, Remírez A, Pio R, Zulueta JJ, Montuenga LM: Molecular profiling of computed tomography screen-detected lung nodules shows multiple malignant features. Cancer Epidemiol Biomarkers Prev; 2006 Feb;15(2):373-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular profiling of computed tomography screen-detected lung nodules shows multiple malignant features.
  • RATIONALE AND PURPOSE: Low-dose spiral computerized axial tomography (spiral CT) is effective for the detection of small early lung cancers.
  • The objective of the current study was to analyze the phenotypic and genetic alterations in the small pulmonary malignancies resected after detection in the University of Navarra/International Early Lung Cancer Action Project spiral CT screening trial and to determine whether their malignant molecular features are similar to those of resected lung tumors diagnosed conventionally.
  • EXPERIMENTAL DESIGN: We analyzed 17 biomarkers of lung epithelial malignancy in a series of 11 tumors resected at our institution during the last 4 years (1,004 high-risk individuals screened), using immunohistochemistry and fluorescence in situ hybridization (FISH).
  • A parallel series of 11 gender-, stage-, and histology-matched lung cancers diagnosed by other means except screening was used as control.
  • RESULTS: The molecular alterations and the frequency of phenotypic or genetic aberrations were very similar when screen-detected and nonscreen-detected lung cancers were compared.
  • Furthermore, most of the alterations found in the screen-detected cancers from this study were concordant with what has been described previously for stage I-II lung cancer.
  • CONCLUSIONS: Small early-stage lung cancers resected after detection in a spiral CT-based screening trial reveal malignant molecular features similar to those found in conventionally diagnosed lung cancers, suggesting that the screen-detected cancers are not overdiagnosed.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / genetics. Lung Neoplasms / genetics. Tomography, Spiral Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16492931.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


17. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E: Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol; 2009 Oct;135(10):1429-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy.
  • Stimulation of angiotensin II type 1 receptors (AT1R) acts proangiogenically by increasing levels of vascular endothelial growth factor (VEGF).
  • METHODS: A total of 287 patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy were retrospectively analysed regarding long-term medication with ACEI and ARB as well as histological type, stage, performance status, gender, age, dose-intensity of chemotherapy and survival.
  • CONCLUSIONS: Addition of ACEI or ARB to platinum-based first-line chemotherapy may contribute to prolonged survival in patients with advanced lung cancer.
  • [MeSH-major] Angiotensin II Type 1 Receptor Blockers / therapeutic use. Angiotensin-Converting Enzyme Inhibitors / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Female. Humans. Male. Middle Aged. Platinum / therapeutic use. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Nephrol. 2003 Dec;14(12):3061-71 [14638905.001]
  • [Cites] Mini Rev Med Chem. 2006 Jul;6(7):835-44 [16842133.001]
  • [Cites] J Clin Invest. 1996 Aug 1;98(3):671-9 [8698858.001]
  • [Cites] Br J Cancer. 2005 Apr 11;92(7):1247-52 [15785746.001]
  • [Cites] Nutr Cancer. 2001;41(1-2):64-9 [12094630.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1504-13 [14508839.001]
  • [Cites] Am J Med. 2008 Aug;121(8 Suppl):S8-15 [18638617.001]
  • [Cites] Oncologist. 2007 Jun;12(6):713-8 [17602060.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Oct;130(10):567-73 [15449186.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):748-57 [18181094.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):6038-45 [14676130.001]
  • [Cites] Ann N Y Acad Sci. 2008 Sep;1138:65-72 [18837885.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4176-9 [12154013.001]
  • [Cites] Trends Endocrinol Metab. 2005 Sep;16(7):293-9 [16061390.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2462-70 [11745304.001]
  • [Cites] Endocr Relat Cancer. 2008 Mar;15(1):277-88 [18310294.001]
  • [Cites] Cochrane Database Syst Rev. 2007 Oct 17;(4):CD004569 [17943820.001]
  • [Cites] Chest. 2006 Oct;130(4):1211-9 [17035458.001]
  • [Cites] J Cell Physiol. 2003 Aug;196(2):370-7 [12811831.001]
  • [Cites] Lancet. 1998 Jul 18;352(9123):179-84 [9683206.001]
  • [Cites] Acta Diabetol. 2005 Apr;42 Suppl 1:S33-41 [15868118.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Semin Oncol. 1988 Dec;15(6 Suppl 7):58-61 [2851181.001]
  • [Cites] J Clin Invest. 2003 Jul;112(1):67-75 [12840060.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1160-74 [18337605.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):271-9 [15637093.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1633-7 [11337361.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):57-66 [18026817.001]
  • [Cites] J Natl Cancer Inst. 2008 Sep 3;100(17):1223-32 [18728281.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):30-6 [15162145.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3601-14 [18728246.001]
  • [Cites] Mol Cancer Ther. 2003 Nov;2(11):1139-47 [14617787.001]
  • [Cites] Int J Urol. 2008 Jan;15(1):19-26 [18184167.001]
  • [Cites] Int J Biochem Cell Biol. 2003 Jun;35(6):881-900 [12676174.001]
  • [Cites] Am Heart J. 2004 Nov;148(5):747-54 [15523303.001]
  • [Cites] Blood. 2004 Jul 15;104(2):402-8 [15044253.001]
  • (PMID = 19399518.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Angiotensin-Converting Enzyme Inhibitors; 49DFR088MY / Platinum
  •  go-up   go-down


18. Miller AA, Wang XF, Gu L, Hoffman P, Khatri J, Dunphy F, Edelman MJ, Bolger M, Vokes EE, Green MR, Cancer and Leukemia Group B (CALGB): Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). J Thorac Oncol; 2008 Oct;3(10):1159-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
  • INTRODUCTION: We investigated dose-dense docetaxel and cisplatin in patients with measurable non-small cell lung cancer in a randomized phase II study without [A] or with [B] a putative chemoprotective agent, BNP7787.
  • PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB (effusion) or IV, performance status 0 to 1, and adequate organ function were eligible.
  • Its further investigation in the curative setting in non-small cell lung cancer should be considered.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Erythropoietin / analogs & derivatives. Granulocyte Colony-Stimulating Factor / therapeutic use. Lung Neoplasms / drug therapy. Mesna / analogs & derivatives
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Adult. Aged. Anemia / drug therapy. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Cisplatin / administration & dosage. Darbepoetin alfa. Dose-Response Relationship, Drug. Drug Therapy, Combination. Feasibility Studies. Female. Filgrastim. Hematinics / therapeutic use. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Neutropenia / drug therapy. Prognosis. Recombinant Proteins. Survival Rate. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DARBEPOETIN ALFA .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827613.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA114558-02; United States / NCI NIH HHS / CA / CA21060; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35113; United States / NCI NIH HHS / CA / CA35421; United States / NCI NIH HHS / CA / CA37447; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA45389; United States / NCI NIH HHS / CA / CA45418; United States / NCI NIH HHS / CA / CA45564; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA74811; United States / NCI NIH HHS / CA / CA77298; United States / NCI NIH HHS / CA / CA77440
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hematinics; 0 / Recombinant Proteins; 0 / Taxoids; 11096-26-7 / Erythropoietin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 15H5577CQD / docetaxel; 15UQ94PT4P / Darbepoetin alfa; 3A58010674 / pegfilgrastim; 45127-11-5 / 2,2'-dithiodiethanesulfonic acid; NR7O1405Q9 / Mesna; PVI5M0M1GW / Filgrastim; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Kadara H, Lacroix L, Behrens C, Solis L, Gu X, Lee JJ, Tahara E, Lotan D, Hong WK, Wistuba II, Lotan R: Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila); 2009 Aug;2(8):702-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system.
  • Lung cancer continues to be a major deadly malignancy.
  • We hypothesized that genes differentially expressed among cells constituting an in vitro human lung carcinogenesis model consisting of normal, immortalized, transformed, and tumorigenic bronchial epithelial cells are relevant to the clinical outcome of non-small cell lung cancer (NSCLC).
  • A subset of these genes (n = 584) separated lung adenocarcinoma clinical samples (n = 361) into two clusters with significant survival differences.
  • The mRNA and protein levels of one these genes-UBE2C-were significantly up-regulated in NSCLC tissue relative to normal lung and increased progressively in lung lesions.
  • Moreover, stage I NSCLC patients with positive UBE2C expression exhibited significantly poorer overall and progression-free survival than patients with negative expression.
  • Our studies with this in vitro model have lead to the identification of a robust six-gene signature, which may be valuable for predicting the survival of lung adenocarcinoma patients.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2001 Jun 7;20(26):3348-53 [11423985.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6014-22 [18829480.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] BMC Cancer. 2001;1:6 [11472637.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):165-9 [12582028.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4167-73 [12874022.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] Cancer Res. 1988 Apr 1;48(7):1904-9 [2450641.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6693-7 [1323115.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):2224-8 [8616876.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1580-6 [9362155.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11891-6 [9751761.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):791-800 [10213214.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1317-21 [10433621.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9027-34 [15604268.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):232-41 [15671551.001]
  • [Cites] Breast Cancer Res. 2005;7(4):171-9 [15987472.001]
  • [Cites] Bioinformatics. 2005 Sep 1;21(17):3524-9 [16081476.001]
  • [Cites] Oncogene. 2005 Nov 21;24(52):7729-45 [16299533.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1121-7 [16489064.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):214-24 [16698281.001]
  • [Cites] Cancer Biol Ther. 2006 Jun;5(6):665-73 [16775421.001]
  • [Cites] Respirology. 2006 Sep;11(5):533-8 [16916324.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11194-206 [17145864.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4259-66 [11709570.001]
  • [Cites] Semin Surg Oncol. 2000 Mar;18(2):106-15 [10657912.001]
  • [Cites] Eur Respir J. 2000 Mar;15(3):547-52 [10759451.001]
  • [Cites] Neoplasia. 2006 Dec;8(12):1062-71 [17217624.001]
  • [Cites] Mol Cell Biol. 2007 Apr;27(8):3176-86 [17283043.001]
  • [Cites] Nature. 2007 Apr 19;446(7138):876-81 [17443180.001]
  • [Cites] Nature. 2007 Apr 19;446(7138):921-5 [17443186.001]
  • [Cites] Nat Rev Genet. 2007 Aug;8(8):601-9 [17607306.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8065-80 [17804718.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] J Clin Invest. 2007 Oct;117(10):2740-50 [17909619.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):564-70 [18385730.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):32-40 [18398830.001]
  • [Cites] Nat Med. 2008 Aug;14(8):822-7 [18641660.001]
  • [Cites] BMC Cancer. 2008;8:238 [18702824.001]
  • [Cites] N Engl J Med. 2008 Sep 25;359(13):1367-80 [18815398.001]
  • [CommentIn] Cancer Prev Res (Phila). 2009 Aug;2(8):695-7 [19638487.001]
  • (PMID = 19638491.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA70907; United States / NCI NIH HHS / CA / P50 CA070907-10; United States / NCI NIH HHS / CA / P30 CA 16672; United States / NCI NIH HHS / CA / P50 CA070907-09; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / UO1 CA86390; United States / NCI NIH HHS / CA / P50 CA070907-11; United States / NCI NIH HHS / CA / U01 CA086390
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 6.3.2.19 / UBE2C protein, human; EC 6.3.2.19 / Ubiquitin-Conjugating Enzymes
  • [Other-IDs] NLM/ NIHMS383276; NLM/ PMC3382104
  •  go-up   go-down


20. Puri V, Garg N, Engelhardt EE, Kreisel D, Crabtree TD, Meyers BF, Patterson GA, Krupnick AS: Tumor location is not an independent prognostic factor in early stage non-small cell lung cancer. Ann Thorac Surg; 2010 Apr;89(4):1053-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor location is not an independent prognostic factor in early stage non-small cell lung cancer.
  • BACKGROUND: Conventional thoracic surgical teaching suggests a worse outcome for lower lobe lung cancers.
  • It is unclear whether this is due to stage migration or whether lobar location is an independent negative prognostic factor.
  • METHODS: We performed a retrospective review of our institutional database of patients undergoing resection for pathologic stage I or stage II lung cancer between Jan 2000 and December 2006.
  • Logistic regression analysis was used to compare the primary dependent variables; age, size, and location of tumor (both laterality and lobe), histology (adenocarcinoma, squamous, large cell, or neuroendocrine and others) and type of resection (wedge, lobectomy or segmentectomy, and pneumonectomy).
  • The three-year and five-year survivals for stage I tumors were 346 of 478 (72.4%) and 277 of 497 (55.7%), respectively.
  • The three-year and five-year survivals for stage II tumors were 81 of 175 (46.3%) and 39 of 150 (26%), respectively, and lobar location did not influence survival.
  • Logistic regression analysis showed that for stage I tumors increasing age and having undergone a pneumonectomy were associated with worse survival, and for stage II tumors increasing age and adenocarcinoma histology were associated with worse survival.
  • CONCLUSIONS: Tumor location within the lung does not predict survival in pathologic stage I/II non-small cell lung carcinoma.
  • Increasing age, adenocarcinoma histology, and pneumonectomy as the resection may lead to worse long-term survival.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / mortality. Lung Neoplasms / pathology


21. Zhao S, Shao K, Ye B, Liu X, Cheng G, Sun K, Meng P, He J: [Prognostic factors for survival after lung cancer surgery in elderly patients]. Zhongguo Fei Ai Za Zhi; 2007 Oct 20;10(5):391-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors for survival after lung cancer surgery in elderly patients].
  • BACKGROUND: With the improvement of the surgical and anesthetic techniques, there are increasing numbers of elderly surgical patients with lung cancer.
  • METHODS: Data were retrospectively analyzed from 192 patients aged ≥70 years who underwent lung cancer surgery.
  • Of these patients, 48.4% were in stage I, 20.8% in stage II, 19.3% in stage III, and 2.1% in stage IV.
  • Tumor characteristics: squamous cell carcinoma 49.0%, adenocarcinoma 35.9%, adenosquamous carcinoma 8.3%, small cell lung cancer 4.7%, others 2.1%.
  • Multivariable COX analysis demonstrated that incomplete resection (P=0.003), advanced surgical-pathological stage (P < 0.001) and other type of the tumor (P=0.016) were significant, independent, unfavorable prognostic determinants in patients.
  • CONCLUSIONS: Thoracic surgery is a safe and feasible approach in elderly patients with lung cancer.
  • Every effort should be made to detect early stage patients who might benefit from surgical treatment.
  • More limited lung surgery may be an adequate alternative in patients with associated co-morbidities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21126407.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


22. Sica G, Yoshizawa A, Sima CS, Azzoli CG, Downey RJ, Rusch VW, Travis WD, Moreira AL: A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol; 2010 Aug;34(8):1155-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors.
  • The concordance of the predominant histologic pattern in the primary tumor and the metastases was of 100% for micropapillary, 86% for solid, 42% for acinar, and 23% for papillary types of adenocarcinoma.
  • Grade I, a pattern with low metastatic potential (BAC); Grade II, patterns with intermediate metastatic potential (acinar and papillary); and Grade III, patterns with high metastatic potential (solid and micropapillary).
  • These grades were combined into a number of different scoring systems, whose ability to predict recurrence or death from disease was tested in 366 stage 1 adenocarcinomas.
  • A score based on the 2 most predominant grades was able to stratify patients into low-to-high risk for recurrence or death of disease (P=0.001).
  • Therefore, this scoring system provides valuable information in discriminating patients with different risk of disease-recurrence in a highly homogeneous population of patients with stage I cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551825.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Archer F, Jacquier E, Lyon M, Chastang J, Cottin V, Mornex JF, Leroux C: Alveolar type II cells isolated from pulmonary adenocarcinoma: a model for JSRV expression in vitro. Am J Respir Cell Mol Biol; 2007 May;36(5):534-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar type II cells isolated from pulmonary adenocarcinoma: a model for JSRV expression in vitro.
  • Ovine pulmonary adenocarcinoma (OPA) is a naturally occurring cancer in sheep, with clinical, radiologic, and histopathologic features similar to that of human pneumonic-type bronchioloalveolar carcinoma.
  • JSRV (Jaagsiekte Sheep RetroVirus) is the etiologic agent of this contagious lung cancer in sheep.
  • Cells involved in the tumor derive from alveolar type II cells and Clara cells, epithelial cells of the distal respiratory tract.
  • In order to investigate the specific interactions between JSRV and alveolar type II cells, we developed an in vitro experimental model in which lung epithelial cells were isolated from OPA and control lungs.
  • Cells in culture expressed alveolar type II cell specific markers such as surfactant protein (SP)-A, SP-C, and a high alkaline phosphatase activity.
  • Alveolar Type II cells derived from tumoral lungs showed a proliferative advantage and expressed the JSRV virus.
  • We thus report on the first in vitro system whereby alveolar type II cells from OPA were efficiently maintained in culture and stably expressed JSRV.
  • This novel experimental model will set up the stage for elucidating lung epithelial transformation in the JSRV-induced tumor.
  • [MeSH-major] Jaagsiekte sheep retrovirus / genetics. Lung Neoplasms / veterinary. Pulmonary Adenomatosis, Ovine / virology. Pulmonary Alveoli / pathology. Pulmonary Alveoli / virology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17158359.001).
  • [ISSN] 1044-1549
  • [Journal-full-title] American journal of respiratory cell and molecular biology
  • [ISO-abbreviation] Am. J. Respir. Cell Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA, Viral; 0 / Pulmonary Surfactant-Associated Protein A; 0 / Pulmonary Surfactant-Associated Protein C; EC 2.7.7.49 / RNA-Directed DNA Polymerase
  •  go-up   go-down


24. Clément-Duchêne C, Krupitskaya Y, Ganjoo K, Lavori P, McMillan A, Kumar A, Zhao G, Padda S, Zhou L, Pedro-Salcedo MS, Colevas AD, Wakelee HA: A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. J Thorac Oncol; 2010 Nov;5(11):1821-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.
  • BACKGROUND: Bevacizumab improves responses and progression-free survival when added to first-line paclitaxel/carboplatin or cisplatin/gemcitabine for patients with advanced nonsquamous non-small cell lung cancer.
  • METHODS: Patients with untreated advanced nonsquamous non-small cell lung cancer, with no evidence of brain metastases and not on anticoagulation were eligible.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3284-9 [19433684.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3217-24 [19433683.001]
  • [Cites] Future Oncol. 2009 Dec;5(10):1545-53 [20001795.001]
  • [Cites] Ann Oncol. 2010 Sep;21(9):1804-9 [20150572.001]
  • [Cites] Lung Cancer. 2010 Dec;70(3):340-6 [20347506.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 9):50-4 [12094340.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):242-7 [12562651.001]
  • [Cites] Eur J Cancer. 1996 Feb;32A(2):243-8 [8664035.001]
  • [Cites] Lung Cancer. 2005 Jan;47(1):69-80 [15603856.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):142-53 [15625369.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8380-8 [16293868.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] J Thorac Oncol. 2008 May;3(5):511-5 [18449004.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 May;8(5):689-99 [18471042.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3543-51 [18506025.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4617-25 [18678835.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1227-34 [19188680.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • (PMID = 20881641.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA124435; United States / NCRR NIH HHS / RR / UL1 RR025744; United States / NCATS NIH HHS / TR / UL1 TR001085
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ NIHMS637070; NLM/ PMC4241413
  •  go-up   go-down


25. Kwon KY, Ro JY, Singhal N, Killen DE, Sienko A, Allen TC, Zander DS, Barrios R, Haque A, Cagle PT: MUC4 expression in non-small cell lung carcinomas: relationship to tumor histology and patient survival. Arch Pathol Lab Med; 2007 Apr;131(4):593-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC4 expression in non-small cell lung carcinomas: relationship to tumor histology and patient survival.
  • It is found in normal adult airway epithelium, non-small cell lung carcinoma (NSCLC) and in other human malignancies independent of mucus secretion.
  • OBJECTIVE: To evaluate the relationship between MUC4 overexpression and long-term survival in patients with NSCLC.
  • Information about long-term survival and tumor stage was collected for all patients.
  • In patients with stage I and II adenocarcinoma, there was a trend toward longer patient survival with higher levels of MUC4 immunoreactivity compared with lower levels (P = .11).
  • CONCLUSION: MUC4 expression is common in pulmonary adenocarcinomas and may indicate a more favorable prognosis in early-stage adenocarcinomas.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / mortality. Lung Neoplasms / pathology. Mucins / biosynthesis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425390.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / Mucin-4; 0 / Mucins
  •  go-up   go-down


26. Kubota K, Niho S, Enatsu S, Nambu Y, Nishiwaki Y, Saijo N, Fukuoka M: Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study. J Thorac Oncol; 2009 Dec;4(12):1530-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.
  • INTRODUCTION: Recent pivotal phase III studies in patients with advanced non-small cell lung cancer (NSCLC) consistently showed greater survival benefit of pemetrexed in patients with nonsquamous cell carcinoma histology (nonsquamous histology) compared with those with squamous cell carcinoma histology (squamous histology).
  • To confirm the efficacy differences of pemetrexed by histologic type, we conducted an additional subgroup analysis of data from a Japanese randomized phase II study evaluating the efficacy and safety of pemetrexed 500 mg/m2 (P500) and 1000 mg/m2 (P1000) in patients with advanced NSCLC previously treated with chemotherapy.
  • The efficacy and safety results of original phase II study have already been reported (Ohe et al., Clin Cancer Res 2008;14:4206-4212).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / therapeutic use. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pemetrexed. Prognosis. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755925.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


27. Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, Swenson BR, Kozower BD, Jones DR: Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer. Eur J Cardiothorac Surg; 2009 Apr;35(4):699-705
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both FDG-PET maximal positron emission tomography (PET) standardized uptake values (SUVmax) and selected tumor markers have been shown to correlate with stage, nodal disease, and survival in esophageal cancer.
  • METHODS: FDG-PET SUVmax was calculated in 67 patients with esophageal cancer of which 59 (88%) had adenocarcinoma.
  • Pathologic staging included stage I (n=29, 43%), stage II (n=19, 28%), stage III disease (n=18, 27%), and stage IV disease (n=1, 2%).
  • PET SUVmax correlated with T stage (p=0.001).

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):663-9 [11505413.001]
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):428-32 [12560430.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Feb;125(2):246-53 [12579092.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 May;125(5):1121-31 [12771886.001]
  • [Cites] Eur J Surg Oncol. 2003 Dec;29(10):890-4 [14624783.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2579-83 [15330218.001]
  • [Cites] Science. 1987 Mar 20;235(4795):1492-5 [3103217.001]
  • [Cites] Annu Rev Physiol. 1992;54:911-30 [1562197.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1637-42 [8253340.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):303-5 [9149888.001]
  • [Cites] Dis Esophagus. 2005;18(3):185-9 [16045581.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1053-9 [15964705.001]
  • [Cites] Ann Thorac Surg. 2006 Mar;81(3):1076-81 [16488726.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):631-4 [16731604.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4283-7 [16857803.001]
  • [Cites] Ann Thorac Surg. 2006 Aug;82(2):391-4; discussion 394-5 [16863735.001]
  • [Cites] Jpn J Clin Oncol. 2006 Jul;36(7):403-9 [16782729.001]
  • [Cites] Ann Surg Oncol. 2006 Aug;13(8):1054-62 [16865594.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):977-91 [17122988.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):658-67 [17211865.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):698-707 [17308274.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Mar;133(3):738-45 [17320575.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1377-83 [17437013.001]
  • [Cites] Lung Cancer. 2008 Feb;59(2):203-10 [17913282.001]
  • (PMID = 19136271.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL007849-09; United States / NHLBI NIH HHS / HL / T32 HL007849; United States / NHLBI NIH HHS / HL / T32 HL007849-09
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / Neoplasm Proteins; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ NIHMS189314; NLM/ PMC2878130
  •  go-up   go-down


28. Kerendi F, Gal A, Corvera JS, Halkos ME, Miller JI: Characteristics of second primary lung malignancy in patients with known breast cancer. South Med J; 2009 Mar;102(3):269-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of second primary lung malignancy in patients with known breast cancer.
  • Identification of a lung nodule in a patient with known breast cancer poses a challenging diagnostic problem.
  • METHODS: From 1977 through 2002, 35 patients with known breast cancer were identified with an additional primary lung cancer.
  • RESULTS: Nineteen patients (54%) were asymptomatic at the time of diagnosis and had their lung cancer discovered during workup and/or follow-up of their breast cancer.
  • The diagnosis of lung cancer was made by preoperative biopsy in 23 patients (82%).
  • Factors associated with a statistically significant improvement in survival included asymptomatic presentation of lung cancer (P = 0.003), absence of tobacco use (P = 0.021), and stage I lung cancer (P = 0.009).
  • Multivariate analysis revealed that tobacco use (RR = 3.6, P = 0.047) and advanced stage of lung cancer (II-IV) at the time of diagnosis (RR = 2.2, P < 0.001) were independent predictors of decreased survival.
  • CONCLUSION: The presentation of a lung nodule in patients with breast cancer warrants a comprehensive evaluation to differentiate between primary lung and metastatic breast cancers, as diagnosis and resection of an early stage lung cancer is associated with improved survival.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis


29. Wei WD, Wen ZS, Su XD, Lin P, Rong TH, Chen LK: [Multivariate survival analysis of 899 patients with non-small cell lung cancer after complete resection]. Ai Zheng; 2007 Nov;26(11):1231-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multivariate survival analysis of 899 patients with non-small cell lung cancer after complete resection].
  • BACKGROUND & OBJECTIVE: Multi-disciplinary management for non-small cell lung cancer (NSCLC) has been applied for more than ten years.
  • The 5-year survival rates were 81.0% for the patients at stage IA, 60.3% for stage IB, 56.9% for stage IIA, 45.7% for stage IIB, 23.5% for stage IIIA, 20.8% for stage IIIB, and 13.0% for stage IV.
  • Univariate analysis showed that T stage, N stage, M stage, histological type, differentiation, chemotherapy for adenocarcinoma (ADC) at stages II and IV, and mediastinal radiotherapy for ADC at stage N2 were prognostic factors.
  • Multivariate analyses showed that histological type, T stage, N stage, M stage and mediastinal radiotherapy for ADC at stage N2 were independent prognostic factors.
  • CONCLUSION: Besides T stage, N stage, and M stage, histological type and mediastinal radiotherapy for ADC at stage N2 are also independent prognostic factors of NSCLC after complete resection.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods


30. West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, Gandara DR: Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol; 2006 Apr 20;24(12):1807-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Advanced bronchioloalveolar carcinoma (BAC) is a distinct subtype of non-small-cell lung cancer (NSCLC) for which there is currently no optimal therapy.
  • Based on preclinical and clinical data suggesting relevance of the epidermal growth factor receptor (EGFR) axis in BAC, the Southwest Oncology Group initiated a phase II trial (S0126) to evaluate the EGFR tyrosine kinase inhibitor gefitinib in chemotherapy-naïve and chemotherapy-pretreated patients with advanced BAC.
  • RESULTS: The median age was 68.0 years (range, 34.3 to 88.6); 51% were female; 89% had a performance status (PS) of 0% or 1% and 11% had a PS of 2.
  • Toxicity consisted mainly of rash and diarrhea, but 2% of patients died of presumed interstitial lung disease.
  • CONCLUSION: Gefitinib is an active agent in advanced stage BAC.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622257.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA58416; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA58882; United States / NCI NIH HHS / CA / CA63844; United States / NCI NIH HHS / CA / CA63848; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA67663; United States / NCI NIH HHS / CA / CA74547; United States / NCI NIH HHS / CA / CA76448; United States / NCI NIH HHS / CA / CA86780
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


31. Wan YW, Sabbagh E, Raese R, Qian Y, Luo D, Denvir J, Vallyathan V, Castranova V, Guo NL: Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction. PLoS One; 2010 Aug 17;5(8):e12222
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction.
  • BACKGROUND: Lung cancer remains the leading cause of cancer-related deaths worldwide.
  • The recurrence rate ranges from 35-50% among early stage non-small cell lung cancer patients.
  • METHODOLOGY/PRINCIPAL FINDINGS: From genome-wide mRNA expression profiles generated on 256 lung adenocarcinoma patients, a 12-gene signature was identified using combinatorial gene selection methods, and a risk score algorithm was developed with Naïve Bayes.
  • This gene signature also stratifies stage I and IB lung adenocarcinoma patients into two distinct survival groups (log-rank P<0.04).
  • The 12-gene risk score is more significant (hazard ratio = 4.19, 95% CI: [2.08, 8.46]) than other commonly used clinical factors except tumor stage (III vs. I) in multivariate Cox analyses.
  • The 12-gene model is more accurate than previously published lung cancer gene signatures on the same datasets.
  • The identified 12 genes exhibit curated interactions with major lung cancer signaling hallmarks in functional pathway analysis.
  • With this 12-gene risk score algorithm, early stage patients at high risk for tumor recurrence could be identified for adjuvant chemotherapy; whereas stage I and II patients at low risk could be spared the toxic side effects of chemotherapeutic drugs.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] Lancet. 2000 Feb 5;355(9202):479-85 [10841143.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] BMC Med Res Methodol. 2002;2:4 [11914137.001]
  • [Cites] Am J Epidemiol. 2004 May 1;159(9):882-90 [15105181.001]
  • [Cites] Science. 2004 Oct 22;306(5696):640-3 [15499008.001]
  • [Cites] J Thorac Cardiovasc Surg. 1988 Sep;96(3):440-7 [2842549.001]
  • [Cites] Stat Med. 1998 Nov 30;17(22):2563-78 [9839348.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Sep 15;172(6):729-37 [15976377.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Science. 2006 May 26;312(5777):1165-8 [16728629.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3344-54 [16740756.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7466-72 [16885343.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4583-9 [16899605.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2606-12 [17088437.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e467 [17194181.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):11-20 [17202451.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):820-32 [17339364.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5562-9 [18065728.001]
  • [Cites] Nat Med. 2008 Aug;14(8):822-7 [18641660.001]
  • [Cites] Int J Oncol. 2009 Jan;34(1):107-15 [19082483.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8213-20 [19088038.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2824-8 [19196983.001]
  • [Cites] J Natl Cancer Inst. 2010 Apr 7;102(7):464-74 [20233996.001]
  • (PMID = 20808922.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016440; United States / NLM NIH HHS / LM / R01 LM009500; United States / PHS HHS / / NIH/NCRR P2016477; United States / NCRR NIH HHS / RR / P20 RR016477; United States / NCRR NIH HHS / RR / P20RR16440; United States / NLM NIH HHS / LM / R01LM009500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Genetic Markers
  • [Other-IDs] NLM/ PMC2923187
  •  go-up   go-down


32. Socinski MA, Blackstock AW, Bogart JA, Wang X, Munley M, Rosenman J, Gu L, Masters GA, Ungaro P, Sleeper A, Green M, Miller AA, Vokes EE: Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol; 2008 May 20;26(15):2457-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
  • PURPOSE: To evaluate 74 Gy thoracic radiation therapy (TRT) with induction and concurrent chemotherapy in stage IIIA/B non-small-cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: Patients with stage IIIA/B NSCLC were randomly assigned to induction chemotherapy with either carboplatin (area under the curve [AUC], 6; days 1 and 22) with paclitaxel (225 mg/m(2); days 1 and 22; arm A) or carboplatin (AUC, 5; days 1 and 22) with gemcitabine (1,000 mg/m(2); days 1, 8, 22, and 29; arm B).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy. Radiotherapy, Conformal. Thoracic Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Adult. Aged. Carboplatin / administration & dosage. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Placebos. Prognosis. Radiotherapy Dosage. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487565.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA16450; United States / NCI NIH HHS / CA / CA21060; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA37135; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA45418; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47577
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Placebos; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


33. Veeramachaneni NK, Battafarano RJ, Meyers BF, Zoole JB, Patterson GA: Risk factors for occult nodal metastasis in clinical T1N0 lung cancer: a negative impact on survival. Eur J Cardiothorac Surg; 2008 Mar;33(3):466-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for occult nodal metastasis in clinical T1N0 lung cancer: a negative impact on survival.
  • BACKGROUND: The application of CT imaging has increased the identification of patients with clinical T1N0 (cT1N0) lung cancer.
  • The optimal management strategy for these early stage lung cancers remains unclear.
  • We analyzed the impact of occult nodal metastasis on cT1N0 lung cancer patients.
  • METHODS: We studied patients with cT1N0 lung cancer enrolled in our database from January 1995 to December 2002.
  • Logistic regression analysis demonstrated a three-fold increase in the risk of having pathologic stage II or stage III disease with every 1.0 cm increase in tumor size (odds ratio 3.2; 95% CI: 2.3-4.6).
  • Median survival was different between pathological stage I (96.3 months), stage II (41.4 months), and stage III (36.1 months) disease (p=0.002).
  • Because of the limitations of clinical staging, we believe that lobectomy and lymph node analysis should be offered to cT1N0 lung cancer patients to provide accurate staging and to optimize multimodality adjuvant treatment of lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / secondary. Aged. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Female. Humans. Logistic Models. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2008 Jun;33(6):1160-1 [18434182.001]
  • (PMID = 18249130.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. Brokx HA, Visser O, Postmus PE, Paul MA: Surgical treatment for octogenarians with lung cancer: results from a population-based series of 124 patients. J Thorac Oncol; 2007 Nov;2(11):1013-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for octogenarians with lung cancer: results from a population-based series of 124 patients.
  • INTRODUCTION: With the increasing life span in the Western world, the number of octogenarians with resectable, localized non-small cell lung cancer is increasing.
  • Previous reports on the outcome of surgery for lung cancer in octogenarians were mainly derived from single institutions.
  • METHODS: General data on all patients diagnosed with lung cancer in the period 1989 to 2004 were retrieved from the Amsterdam Cancer Registry.
  • Absolute and relative survival for octogenarians relative to other age groups and relative to other treatment modalities in octogenarians with clinical stage I/II lung cancer was performed.
  • RESULTS: Non-small cell lung cancer was diagnosed in 1993 octogenarians (14% of all lung cancer patients).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / surgery. Carcinoma, Large Cell / epidemiology. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17975492.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


35. Liu Y, Xu ML, Zhong HH, Heng WJ, Wu BQ: EGFR mutations are more frequent in well-differentiated than in poor-differentiated lung adenocarcinomas. Pathol Oncol Res; 2008 Dec;14(4):373-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR mutations are more frequent in well-differentiated than in poor-differentiated lung adenocarcinomas.
  • Somatic mutations in epidermal growth factor receptor (EGFR) tyrosine kinase domain, particularly deletions in exon 19 and point mutation in exon 21, are associated with clinical outcome in patients with lung adenocarcinoma, suggesting that EGFR mutation would have an important role in clinical decision making.
  • DNA was extracted from the excised specimens of 60 lung adenocarcinoma patients with phenol-chloroform and ethanol precipitation.
  • This trend was also observed in the patients with pathologic stage I-II compared with stage III-IV, but neither of them was statistically significant.
  • In conclusion, our study suggest that EGFR mutations may be a valuable prognostic factor for disease free survival of surgically treated lung adenocarcinoma patients independently from adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]
  • [Cites] Eur J Cancer. 2006 Jan;42(1):17-23 [16364841.001]
  • [Cites] Science. 2003 May 9;300(5621):949 [12738854.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):857-65 [15681531.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1167-73 [15709185.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1103-9 [15020612.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2244-51 [15788673.001]
  • [Cites] Lung Cancer. 2006 Apr;52(1):47-52 [16503085.001]
  • [Cites] Cell Res. 2005 Mar;15(3):212-7 [15780185.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Ai Zheng. 2005 Aug;24(8):919-23 [16086866.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1453-61 [14519751.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2106-10 [15788655.001]
  • [Cites] Lung Cancer. 2005 Oct;50(1):25-33 [16011858.001]
  • [Cites] Lung Cancer. 2005 Oct;50(1):1-8 [15950315.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2513-20 [15738541.001]
  • [Cites] Br J Cancer. 2005 Aug 8;93(3):355-63 [16052218.001]
  • [Cites] Oncologist. 1998;3(1):35-44 [10388082.001]
  • (PMID = 18985444.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


36. Akerley W, Boucher KM, Bentz JS, Arbogast K, Walters T: A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer. J Thorac Oncol; 2009 Feb;4(2):214-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.
  • INTRODUCTION: Erlotinib improves survival in patients with advanced non-small cell lung cancer who have been previously treated with systemic chemotherapy.
  • METHODS: Eligibility criteria included stage IIIB/IV or recurrent non-small cell lung cancer, no prior chemotherapy for systemic disease, performance status = 0 to 1, no history of brain metastases, and weight loss less than 10%.
  • Histologies were adenocarcinoma in 22 and squamous cell in six.
  • CONCLUSIONS: Despite a modest response rate, lack of enrichment for never-smokers and absence of conventional chemotherapy in many patients, the median and long-term survivals were comparable with those expected after conventional sequencing of chemotherapy.
  • Erlotinib as initial therapy was well tolerated and warrants randomized evaluation as first-line treatment for advanced lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Erlotinib Hydrochloride. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179899.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


37. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst; 2005 Mar 2;97(5):339-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
  • BACKGROUND: Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene in lung cancers are associated with increased sensitivity of these cancers to drugs that inhibit EGFR kinase activity.
  • However, the role of such mutations in the pathogenesis of lung cancers is unclear.
  • METHODS: We sequenced exons 18-21 of the EGFR TK domain from genomic DNA isolated from 617 non-small-cell lung cancers (NSCLCs) and 524 normal lung tissue samples from the same patients and 36 neuroendocrine lung tumors collected from patients in Japan, Taiwan, the United States, and Australia and from 243 other epithelial cancers.
  • Mutation status was compared with clinicopathologic features and with the presence of mutations in KRAS, a gene in the EGFR signaling pathway that is also frequently mutated in lung cancers.
  • RESULTS: We detected a total of 134 EGFR TK domain mutations in 130 (21%) of the 617 NSCLCs but not in any of the other carcinomas, nor in nonmalignant lung tissue from the same patients.
  • EGFR TK domain mutation status was not associated with patient age at diagnosis, clinical stage, the presence of bronchioloalveolar histologic features, or overall survival.
  • CONCLUSIONS: Mutations in either the EGFR TK domain or the KRAS gene can lead to lung cancer pathogenesis.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2005 Mar 2;97(5):326-8 [15741561.001]
  • [CommentIn] J Natl Cancer Inst. 2006 Mar 1;98(5):362-3; author reply 363-4 [16507834.001]
  • (PMID = 15741570.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R37 HL063762; United States / NCI NIH HHS / CA / 5U01CA8497102; United States / NCI NIH HHS / CA / P50CA70907
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


38. Yan S, Shun-Chang J, Li C, Jie L, Ya-Li L, Ling-Xiong W: Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer. BMC Cancer; 2010;10:621
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer.
  • BACKGROUND: Adjuvant chemotherapy has been shown to improve survival rates of postoperative patients with non-small cell lung cancer (NSCLC).
  • The objective of this study was to explore the possible prognostic and predictive role of topoisomerase II alpha (TopIIα) expression level in postoperative NSCLC patients who received adjuvant chemotherapy.
  • METHODS: Patients with stage I-III NSCLC, who underwent surgery in our hospital from January 2004 to December 2007 and who also received adjuvant chemotherapy after surgery, were analyzed in this study.
  • Univariate survival analysis showed that male sex (P = 0.036), non-adenocarcinoma (P = 0.004), earlier pathological TNM stage (P = 0.001) or pathological N stage (P < 0.001), and high expression of TopIIα (P = 0.012) were correlated with better DFS, whereas age, smoking history, different chemotherapy regimens, T stage and expression level of Ki67 were of no prognostic significance.
  • COX multivariate analysis showed that pathological TNM stage, histological subtype and expression level of TopIIα to be independent of risk factors affecting DFS in postoperative NSCLC patients who received chemotherapy.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / enzymology. Carcinoma, Non-Small-Cell Lung / surgery. Chemotherapy, Adjuvant / methods. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Lung Neoplasms / drug therapy. Lung Neoplasms / enzymology. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1999;10 Suppl 5:S83-6 [10582146.001]
  • [Cites] J Cancer Res Clin Oncol. 2010 Jul;136(7):1029-37 [20052594.001]
  • [Cites] Lung Cancer. 2001 May;32(2):117-28 [11325482.001]
  • [Cites] Anticancer Res. 2001 Mar-Apr;21(2A):905-10 [11396183.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):235-43 [12067686.001]
  • [Cites] Int J Oncol. 2004 Jan;24(1):201-9 [14654958.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3965-70 [14666704.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):351-60 [14736927.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3860-7 [15326194.001]
  • [Cites] Cancer Res. 1987 Oct 15;47(20):5455-60 [2888532.001]
  • [Cites] J Natl Cancer Inst. 1992 Jan 15;84(2):113-8 [1310509.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7):1666-74 [1312895.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):456-63 [8382508.001]
  • [Cites] Biochim Biophys Acta. 1995 Dec 27;1264(3):337-46 [8547322.001]
  • [Cites] Br J Cancer. 1996 Dec;74(12):1869-76 [8980384.001]
  • [Cites] Breast Cancer Res Treat. 1999 May;55(1):61-71 [10472780.001]
  • [Cites] J Clin Oncol. 2005 May 10;23(14):3270-8 [15886314.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R374-84 [15987433.001]
  • [Cites] Mol Pharmacol. 2005 Sep;68(3):625-34 [15942022.001]
  • [Cites] Lancet Oncol. 2006 Sep;7(9):719-27 [16945766.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):994-9 [17289895.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2893-8 [17363613.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):736-44 [18258981.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] BMC Cancer. 2009;9:72 [19250538.001]
  • [Cites] Lancet Oncol. 2009 Oct;10(10):1001-10 [19796752.001]
  • [Cites] Ann Surg Oncol. 2010 May;17(5):1392-7 [20217261.001]
  • [Cites] Future Oncol. 2010 May;6(5):741-67 [20465389.001]
  • [Cites] Pathobiology. 2000 May-Jun;68(3):137-43 [11174071.001]
  • (PMID = 21067592.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2988758
  •  go-up   go-down


39. Chen QL, Zheng WL, Yao WJ, Nie LW, Cheng SH, Ma WL: Analysis of SOX4 gene mutation in non-small cell lung cancer tissues. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Oct;24(5):505-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of SOX4 gene mutation in non-small cell lung cancer tissues.
  • OBJECTIVE: To investigate the mutation of SOX4 gene in the different tumor tissues with pathological stages and types of non-small cell lung cancer (NSCLC), and to explore its roles in the progression of lung carcinoma.
  • METHODS: The SOX4 gene HMG-box of lung cancer tissues and paracancerous tissues were amplified by PCR, 20 cases shown difference by single strand conformation polymorphyism analysis were sequenced.
  • Seven were detected from squamous cell carcinoma, five from adenocarcinoma and six from adeno-squamous.
  • Three were obtained from tissues in stage I, five in stage II, six in stage III, and four in stage IV.
  • The mutation rate in stage II, III and IV was significantly higher than that in stage I.
  • The results indicate that the SOX4 gene mutations might be related in the lung carcinogenesis and tumor metastasis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Mutation. SOXC Transcription Factors / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922414.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / SOX4 protein, human; 0 / SOXC Transcription Factors
  •  go-up   go-down


40. Mao N, Zuo C, Gan N, Zhu J, Huang D, Liu D, Xie T, Pan H, Huang Y: [Trachea-bronchoplasty in the treatment of centrally located lung cancer]. Zhongguo Fei Ai Za Zhi; 2005 Aug 20;8(4):329-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Trachea-bronchoplasty in the treatment of centrally located lung cancer].
  • BACKGROUND: To maximize the preservation of functional pulmonary parenchyma and improve the quality of life of patients with centrally located lung cancer, trachea-bronchoplasty has been used in clinical application with good efficacy.
  • The aim of this study is to explore the appropriate admission and management of trachea-bronchoplasty and prevent complications of trachea-bronchial sleeve resection in the treatment of centrally located lung cancer.
  • METHODS: Seventy-six patients with central lung cancer, who were treated with trachea-bronchoplasty from June, 1988 to October, 2004, were analyzed.
  • There were 49 cases of squamous cell carcinoma, 16 adenocarcinoma, 7 adenosquamous carcinoma, 3 small cell lung cancer and 1 adenoid cystic adenocarcinoma.
  • Seventeen patients were in stage I, 39 in stage II, 17 in stage IIIA and 3 in stage IIIB.
  • CONCLUSIONS: The trachea-bronchoplasty can not only preserve functional pulmonary parenchyma as much as possible and improve the quality of life of patients, but also provide an operative opportunity to those patients with poor pulmonary function in the treatment of centrally located lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21108894.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


41. Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE: Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol; 2008 Sep;3(9):1003-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
  • INTRODUCTION: This Phase I trial aimed to determine the maximum-tolerated-dose of erlotinib administered with two standard chemoradiotherapy regimens for non-small cell lung cancer.
  • METHODS: Unresectable stage III non-small cell lung cancer patients were enrolled in this 2-arm dose-escalation study.
  • PATIENT CHARACTERISTICS: performance status 0 to 24 patients, 1 to 10 patients, median age 63 years, adenocarcinoma 21% and female 14 patients.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758303.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009566-15; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / P30 CA14599-32; United States / NCI NIH HHS / CA / CA009566-15; United States / NCI NIH HHS / CM / N01 CM007003; United States / NCI NIH HHS / CM / N01 CM-07003-74; United States / NCI NIH HHS / CA / T32 CA009566
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / Taxoids; 15H5577CQD / docetaxel; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS154299; NLM/ PMC4535721
  •  go-up   go-down


42. Sousa M, Cavadas S, Moreira MJ, Mellidez JC: Long survival with erlotinib as second line treatment in non-small cell lung cancer. Rev Port Pneumol; 2008 Oct;14 Suppl 3:S85-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long survival with erlotinib as second line treatment in non-small cell lung cancer.
  • [Transliterated title] Longa sobrevida com erlotinib como tratamento de segunda linha do cancro do pulmão de não pequenas células.
  • The pleural liquid study, the bronchofiberscope examination, the biopsy and the studies for cancer staging allowed the diagnosis: Lung Adenocarcinoma stage IIIB (positive pleural effusion) - December 2005.
  • He maintains the same treatment with disease stability and a general good condition, only showing a grade II rash (face, forearms and hands) as secondary effect of treatment.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 Sociedade Portuguesa de Pneumologia/SPP.
  • (PMID = 25967693.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Lung cancer / Neoplasia do pulmão / adenocarcinoma / carboplatin / erlotinib / gemcitabine / primeira linha de tratamento / tratamento com erlotinib
  •  go-up   go-down


43. Kim YS, Yoon SM, Choi EK, Yi BY, Kim JH, Ahn SD, Lee SW, Shin SS, Lee JS, Suh C, Kim SW, Kim DS, Kim WS, Park HJ, Park CI: Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys; 2005 May 1;62(1):76-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer.
  • PURPOSE: To evaluate the efficacy and toxicity of concurrent chemoradiotherapy with paclitaxel/cisplatin for Stage IIIB locally advanced non-small-cell lung cancer (NSCLC).
  • The 2-year overall and progression-free survival rates were 37% and 18%, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Dose Fractionation. Female. Humans. Male. Middle Aged. Multivariate Analysis. Paclitaxel / administration & dosage. Prospective Studies. Survival Analysis. Treatment Outcome


44. Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, Uchida O, Usuda J, Kato H: The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg; 2007 Apr;13(2):73-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer.
  • Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung cancers, with patients having a poor prognosis.
  • Approximately one third of NSCLC patients present with early-stage disease in which potentially curative resection and multi-modality therapy.
  • Although adjuvant chemotherapy is the standard practice for patients with stages I-III breast and colorectal cancer, the therapeutic efficacy of adjuvant chemotherapy, following complete surgical resection of early stage NSCLC, has not been fully established.
  • Several prospective randomized trials for patients with early stage NSCLC (stages I-IIIA) have confirmed a survival benefit with cisplatin-based adjuvant chemotherapy, as demonstrated in the 1995 meta-analysis performed by the NSCLC Collaborative Group.
  • Studies from Japan have reported that adjuvant therapy with uracil-tegaful (UFT) afforded an improvement of 4% in the 5-year survival rate and a relative risk reduction of 26% in mortality at 5 years among patients with T1-2N0 (stage I) disease.
  • In particular, the Japan Lung Cancer Research Group has demonstrated an improvement in the 5-year survival rate of 11%, favoring chemotherapy with UFT in the subset of patients with T2N0 (stage IB) disease.
  • The Lung Adjuvant Cisplatin Evaluation (LACE), which was based on a pooled analysis of five randomized trials, has demonstrated that cisplatin-based adjuvant chemotherapy improved survival in patients with completely resected NSCLC.
  • This benefit depended on stage, being greatest in patients with stage II or IIIA disease.
  • This analysis has suggested that platinum-based adjuvant chemotherapy may have no benefit for patients with stage IA and only a marginal benefit for patients with stage IB.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / mortality

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17505412.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 18
  •  go-up   go-down


45. Spigel DR, Greco FA, Thompson DS, Webb C, Rubinsak J, Inhorn RC, Reeves J Jr, Vazquez ER, Lane CM, Burris HA 3rd, Hainsworth JD: Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer. Clin Lung Cancer; 2010 May;11(3):198-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer.
  • BACKGROUND: Targeting epidermal growth factor receptors (EGFRs) has been a novel strategy in treating non-small-cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: Eligibility criteria were newly diagnosed unresectable stage III/IV NSCLC, all histologies, measurable disease, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2.
  • Patients had a median age of 69 years; 70% were male and 30% were female; ECOG PS was 0 in 42%, 1 in 51%, and 2 in 7%; patients had adenocarcinoma (42%), squamous cell (30%), large cell (6%), mixed (1%), and not otherwise specified (20%) disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20439197.001).
  • [ISSN] 1938-0690
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; PQX0D8J21J / Cetuximab
  •  go-up   go-down


46. Kubota K, Nishiwaki Y, Tamura T, Nakagawa K, Matsui K, Watanabe K, Hida T, Kawahara M, Katakami N, Takeda K, Yokoyama A, Noda K, Fukuoka M, Saijo N: Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol; 2008 Dec;3(12):1439-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.
  • INTRODUCTION: The aim of this study was to evaluate the efficacy and safety of Erlotinib in Japanese patients with previously treated non-small cell lung cancer (NSCLC).
  • METHODS: This open-label phase II trial enrolled stage III/IV NSCLC patients who had progressive disease after at least one prior platinum-based chemotherapy regimen.
  • Three patients who had deletion mutations on exon 19 (del E746-A750 or del S752-I759) exhibited objective response.
  • Four patients (6%) experienced interstitial lung disease-like events, one of whom died.
  • The toxicity profile was similar to that in Western patients, except for a somewhat higher incidence of skin disorders and interstitial lung disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Salvage Therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Asian Continental Ancestry Group. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Disease-Free Survival. Erlotinib Hydrochloride. Female. Humans. Male. Middle Aged. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19057270.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


47. Frey A, Soubani AO, Adam AK, Sheng S, Pass HI, Lonardo F: Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival. Histopathology; 2009 Apr;54(5):590-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival.
  • AIMS: To evaluate whether there is a correlation between the subcellular localization of maspin and the histological, molecular and biological features of pulmonary adenocarcinoma, particularly addressing the hypothesis that the tumour inhibitor properties of maspin may be linked to a nuclear, compared with a combined nuclear and cytoplasmic expression pattern.
  • METHODS AND RESULTS: The subcellular expression of maspin was determined in 80 resected pulmonary adenocarcinomas (Stage I, 46; Stage II, 10; Stage III, 20; Stage IV, 4) and correlated with histological grade, proliferative rate, p53 expression, vascular endothelial growth factor (VEGF)-A levels, and prognosis (mean follow-up of 41.5 months).
  • Cox multivariate analysis revealed in stage I adenocarcinomas (N) maspin as the only predictor of improved survival.
  • CONCLUSIONS: (N) maspin selects lung adenocarcinomas with distinct molecular and clinical features, supporting the hypothesis that its tumour inhibitor properties may be linked to its nuclear localization.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2001 Jan-Feb;8(1):72-9 [11206229.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3691-8 [17530022.001]
  • [Cites] Clin Biochem. 2001 Jun;34(4):303-7 [11440731.001]
  • [Cites] J Pathol. 2001 Oct;195(3):321-6 [11673829.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):54-60 [11801540.001]
  • [Cites] Int J Cancer. 2002 Aug 1;100(4):452-5 [12115529.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2924-32 [12231537.001]
  • [Cites] Exp Cell Res. 2003 Jan 15;282(2):59-69 [12531692.001]
  • [Cites] J Pathol. 2003 Apr;199(4):432-5 [12635133.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):863-70 [12644823.001]
  • [Cites] Histopathology. 2003 Jun;42(6):541-5 [12786889.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1883-90 [12820473.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8677-87 [14647462.001]
  • [Cites] J Clin Pathol. 2004 Jun;57(6):591-7 [15166262.001]
  • [Cites] Lung Cancer. 2004 Aug;45(2):197-205 [15246191.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Aug;130(8):475-9 [15197584.001]
  • [Cites] World J Gastroenterol. 2004 Sep 15;10(18):2624-7 [15309707.001]
  • [Cites] Ann Rheum Dis. 2004 Oct;63(10):1205-11 [15361372.001]
  • [Cites] Science. 1994 Jan 28;263(5146):526-9 [8290962.001]
  • [Cites] Oncogene. 1996 Nov 7;13(9):1983-90 [8934545.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2470-6 [10344760.001]
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):248-53 [15620951.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1059:11-5 [16382038.001]
  • [Cites] Lung Cancer. 2006 Jan;51(1):31-9 [16159682.001]
  • [Cites] Lung Cancer. 2006 Mar;51(3):323-8 [16406136.001]
  • [Cites] Gynecol Oncol. 2006 Jun;101(3):385-9 [16443262.001]
  • [Cites] Curr Opin Cell Biol. 2006 Oct;18(5):524-32 [16908128.001]
  • [Cites] J Cell Physiol. 2006 Dec;209(3):631-5 [17001674.001]
  • [Cites] J Cell Physiol. 2006 Dec;209(3):617-24 [17001697.001]
  • [Cites] Ann Surg Oncol. 2006 Nov;13(11):1517-23 [17009165.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7279-83 [17189399.001]
  • [Cites] Oral Oncol. 2007 Mar;43(3):272-7 [17174141.001]
  • [Cites] J Clin Pathol. 2007 May;60(5):483-6 [16698957.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Sep;26(3):301-5 [17987787.001]
  • [Cites] Cancer Detect Prev. 2001;25(3):268-79 [11425269.001]
  • (PMID = 19309490.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA084176-07; United States / NCI NIH HHS / CA / R01 CA084176; United States / NCI NIH HHS / CA / R01 CA084176-07
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins; 0 / Tumor Suppressor Protein p53; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ NIHMS218465; NLM/ PMC2911575
  •  go-up   go-down


48. Zhang S, Qiu X, Gu Y, Wang E: Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer. Lung Cancer; 2008 Dec;62(3):295-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer.
  • However, the involvement of PYK2 in human non-small cell lung cancer (NSCLC) has not yet been determined.
  • In the present study, 90 patients with NSCLC (represented by adenocarcinoma and squamous cell carcinoma) were included retrospectively.
  • Patients with higher expression of PYK2 had advanced stage of NSCLCs (I+II versus III+IV, p=0.012).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / enzymology. Focal Adhesion Kinase 2 / metabolism. Lung Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / secondary. Blotting, Western. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / secondary. Extracellular Signal-Regulated MAP Kinases / metabolism. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Lung / enzymology. Lung / pathology. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Retrospective Studies. Up-Regulation


49. Hata M, Tokuuye K, Kagei K, Sugahara S, Nakayama H, Fukumitsu N, Hashimoto T, Mizumoto M, Ohara K, Akine Y: Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. Int J Radiat Oncol Biol Phys; 2007 Jul 1;68(3):786-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study.
  • PURPOSE: To present treatment outcomes of hypofractionated high-dose proton beam therapy for Stage I non-small-cell lung cancer (NSCLC).
  • METHODS AND MATERIALS: Twenty-one patients with Stage I NSCLC (11 with Stage IA and 10 with Stage IB) underwent hypofractionated high-dose proton beam therapy.
  • Histology was squamous cell carcinoma in 6 patients, adenocarcinoma in 14, and large cell carcinoma in 1.
  • The 2-year overall and cause-specific survival rates were 74% and 86%, respectively.
  • Five patients showed recurrences 6-29 months after treatment, including local progression and new lung lesions outside of the irradiated volume in 1 and 4 patients, respectively.
  • CONCLUSIONS: Hypofractionated high-dose proton beam therapy seems feasible and effective for Stage I NSCLC.
  • Proton beams may contribute to enhanced efficacy and lower toxicity in the treatment of patients with Stage I NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Dose Fractionation. Lung Neoplasms / radiotherapy. Neoplasm Recurrence, Local / prevention & control. Protons / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17379439.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


50. Tamura K, Okamoto I, Kashii T, Negoro S, Hirashima T, Kudoh S, Ichinose Y, Ebi N, Shibata K, Nishimura T, Katakami N, Sawa T, Shimizu E, Fukuoka J, Satoh T, Fukuoka M, West Japan Thoracic Oncology Group: Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer; 2008 Mar 11;98(5):907-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).
  • The purpose of this study was to evaluate the efficacy of gefitinib and the feasibility of screening for epidermal growth factor receptor (EGFR) mutations among select patients with advanced non-small cell lung cancer (NSCLC).
  • Stage IIIB/IV NSCLC, chemotherapy-naive patients or patients with recurrences after up to two prior chemotherapy regimens were eligible.
  • This trial documents the feasibility of performing a multicentre phase II study using a central typing laboratory, demonstrating the benefit to patients of selecting gefitinib treatment based on their EGFR mutation status.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Mutation. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Aged. Aged, 80 and over. Disease Progression. Female. Gene Amplification. Humans. Male. Middle Aged. Prospective Studies


51. Reyes-Gibby CC, Shete S, Yennurajalingam S, Frazier M, Bruera E, Kurzrock R, Crane CH, Abbruzzese J, Evans D, Spitz MR: Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. J Pain Symptom Manage; 2009 Dec;38(6):894-902
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes.
  • We previously demonstrated that select cytokine gene polymorphisms in interleukin (IL)-8 are a significant predictor of pain and analgesia in patients with lung cancer.
  • We evaluated a series of patients with histologically confirmed adenocarcinoma of the pancreas (n=484), who had completed a self-administered survey of pain before initiating any cancer treatment.
  • Severe pain varied by the stage of disease (odds ratio [OR] Stage II=4.02, 95% confidence interval (CI)=1.07, 15.07; Stage III=5.02, 95% CI=1.28, 19.61; Stage IV=6.90, 95% CI=1.96, 24.29), ethnicity (OR non-Hispanic blacks=3.67; 95% CI=1.44, 9.38), reports of depressed mood (OR=1.94; 95% CI=1.09, 3.43), and female sex (OR=1.78; 95% CI=1.04, 3.05).

  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2007 Jun 7;447(7145):655-60 [17554299.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2727-36 [15526319.001]
  • [Cites] Lancet Oncol. 2008 Aug;9(8):777-85 [18672213.001]
  • [Cites] J Intern Med. 2005 Feb;257(2):139-55 [15656873.001]
  • [Cites] Eur J Pharmacol. 2000 Jan 3;387(1):111-8 [10633169.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1755-60 [15665080.001]
  • [Cites] Behav Brain Res. 2006 Feb 28;167(2):355-64 [16256210.001]
  • [Cites] Head Neck. 2006 Apr;28(4):313-20 [16200627.001]
  • [Cites] Neurosci Lett. 2006 Aug 14;404(1-2):154-8 [16777324.001]
  • [Cites] Pain. 2006 Dec 15;126(1-3):294-308 [16949747.001]
  • [Cites] Urology. 2000 Dec 20;56(6):899-905 [11113727.001]
  • [Cites] Oncology (Williston Park). 2000 Nov;14(11A):135-50 [11195407.001]
  • [Cites] J Neurosci. 2001 Jul 15;21(14):5027-35 [11438578.001]
  • [Cites] Eur Spine J. 2002 Feb;11(1):62-6 [11931066.001]
  • [Cites] Adv Exp Med Biol. 2003;521:1-21 [12617561.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2004 Jan 1;124B(1):50-3 [14681913.001]
  • [Cites] Am J Med. 2004 Mar 1;116(5):318-24 [14984817.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Qual Life Res. 2004 Oct;13(8):1369-79 [15503832.001]
  • [Cites] Brain Res. 1994 Aug 15;654(1):15-26 [7982088.001]
  • [Cites] Life Sci. 1995;57(11):1011-26 [7658909.001]
  • [Cites] Med Care. 1996 Mar;34(3):220-33 [8628042.001]
  • [Cites] Pain. 1995 Dec;63(3):289-302 [8719529.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7710-3 [10393885.001]
  • [Cites] Pain. 1999 Sep;82(3):263-74 [10488677.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2745-51 [18086782.001]
  • (PMID = 19692203.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA128069; United States / NCI NIH HHS / CA / R03 CA128069-01A2; United States / NCI NIH HHS / CA / CA128069-01A2; United States / NCI NIH HHS / CA / K07 CA109043-05; United States / NCI NIH HHS / CA / CA109043-05; United States / NCI NIH HHS / CA / K07 CA109043; United States / NCI NIH HHS / CA / CA128069; United States / NCI NIH HHS / CA / P20 CA101936; United States / NCI NIH HHS / CA / CA101936; United States / NCI NIH HHS / CA / CA109043
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics; 0 / Cytokines
  • [Other-IDs] NLM/ NIHMS131146; NLM/ PMC2795073
  •  go-up   go-down


52. Schütte W, Nagel S, Schaedlich S, Brust D, Blankenburg T: Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program. Onkologie; 2005 Apr;28(4):195-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program.
  • BACKGROUND: The molecular genesis of lung cancer and its treatment remain hot spots of medical research because of the high mortality rates especially associated with non-small-cell lung cancer (NSCLC).
  • Adenocarcinoma histology and former nicotine abstention seem to favor sensitivity to gefitinib.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Palliative Care / methods. Quinazolines / administration & dosage. Risk Assessment / methods. Terminal Care / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15840967.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


53. Vicidomini G, Santini M, Fiorello A, Parascandolo V, Calabrò B, Pastore V: Intraoperative pleural lavage: is it a valid prognostic factor in lung cancer? Ann Thorac Surg; 2005 Jan;79(1):254-7; discussion 254-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative pleural lavage: is it a valid prognostic factor in lung cancer?
  • BACKGROUND: In patients undergoing lung resection for non-small cell lung cancer (NSCLC), the primary TNM (tumor-regional lymph node-distant metastasis) staging system is the best prognostic factor.
  • METHODS: We enrolled 84 patients (79 men, 5 women) aged between 36 and 81 years (mean age, 64.8 years) undergoing a major lung resection for NSCLC, with no preoperative evidence of pleural effusions.
  • The lavage was positive in 7.3% in patients with early stage I disease (3/41) and 37.2% in patients with stage II/III disease.
  • CONCLUSIONS: A positive cytology finding of intraoperative pre-resectional pleural lavage could be an important prognostic factor in patients undergoing major lung resection for NSCLC.
  • However, larger series are needed to define accurately the role of this technique in early stage lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Intraoperative Care / methods. Lung Neoplasms / pathology. Pleural Cavity / cytology. Pleural Effusion, Malignant / diagnosis. Therapeutic Irrigation
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Humans. Life Tables. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pneumonectomy. Predictive Value of Tests. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2005 Oct;80(4):1564; author reply 1565 [16181927.001]
  • (PMID = 15620952.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


54. Endo S, Saito N, Hasegawa T, Sato Y, Sohara Y: Pulmonary cryptococcosis mimicking pulmonary metastases in a patient treated with Tegafur-uracil after lung cancer surgery. Jpn J Thorac Cardiovasc Surg; 2005 Jul;53(7):369-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary cryptococcosis mimicking pulmonary metastases in a patient treated with Tegafur-uracil after lung cancer surgery.
  • A 71-year-old man who had undergone surgery for stage II adenocarcinoma of the lung followed by adjuvant tegafur-uracil (UFT; 300 mg/day) therapy was admitted.
  • Physicians need to be aware of the possibility of pulmonary cryptococcosis mimicking pulmonary metastases in patients treated with UFT after surgery for lung cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cryptococcosis / diagnosis. Lung Diseases, Fungal / diagnosis. Lung Neoplasms / diagnosis. Lung Neoplasms / therapy

  • Genetic Alliance. consumer health - Cryptococcosis.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1967 Oct;67(4):724-32 [6069972.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1992 Mar;30(3):393-401 [1569717.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 1998 Dec;36(12 ):1038-42 [10064958.001]
  • [Cites] AJR Am J Roentgenol. 1984 May;142(5):893-6 [6609567.001]
  • [Cites] J Comput Assist Tomogr. 2002 May-Jun;26(3):330-4 [12016357.001]
  • [Cites] Br J Radiol. 2002 Mar;75(891):275-8 [11932223.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] Chest. 2003 Dec;124(6):2143-7 [14665493.001]
  • [Cites] Gan To Kagaku Ryoho. 1988 Jun;15(6):1915-20 [3132895.001]
  • (PMID = 16095237.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 1-UFT protocol
  •  go-up   go-down


55. Xu AH, Yin YW, Chen FH: [The value of serum endostatin level in early diagnosis of lung cancer]. Zhonghua Yi Xue Za Zhi; 2006 Jul 18;86(27):1916-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The value of serum endostatin level in early diagnosis of lung cancer].
  • OBJECTIVE: To investigate value of serum endostatin level in early diagnosis of lung cancer.
  • METHODS: ELISA was used to detect the level of serum endostatin at in 40 lung carcinoma patients, 18 males and 4 females, aged 59.50 +/- 14.58.
  • The serum endostatin levels of the lung cancer patients at different clinical stage and of different pathological types were analyzed.
  • Twenty patients with benign lung disease and 20 normal persons were used as controls. RESULTS:.
  • (1) The serum endostatin level of the lung cancer patients was 10.71 +/- 9.99) ng/ml, significantly higher than those of the patients with benign lung diseases and the normal persons (4.79 +/- 1.23 ng/ml and 4.51 +/- 1.14 ng/ml, respectively, both P < 0.01). (2) The serum endostatin level of the lung cancer patients at the stage I and II were 13.63 +/- 13.13 ng/ml and 12.35 +/- 5.79 ng/ml respectively, booth significantly higher than that of the patients at the stage III (6.29 +/- 1.64, P = 0.023 and P = 0.023). (3) There were no significant differences in the serum endostatin level among the lung cancer patients with different pathological types. (4) The serum endostatin level of the lung cancer patients after chemotherapy was 7.83 +/- 1.48 ng/ml, significantly higher than that before the chemotherapy (5.59 +/- 1.74, P = 0.04).
  • CONCLUSION:. (1) Rising in lung cancer at stages I and II, level of serum may probably be used as the a sign in early diagnosis of lung cancer. (2) After chemotherapy the level of endostatin has a trend of rising.
  • [MeSH-major] Endostatins / blood. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Early Diagnosis. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Serologic Tests

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064531.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Endostatins
  •  go-up   go-down


56. Comella P, Filippelli G, De Cataldis G, Massidda B, Frasci G, Maiorino L, Putzu C, Mancarella S, Palmeri S, Cioffi R, Roselli M, Buzzi F, Milia V, Gambardella A, Natale D, Bianco M, Ghiani M, Masullo P, Southern Italy Cooperative Oncology Group: Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol; 2007 Feb;18(2):324-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101).
  • BACKGROUND: Triplet regimens were occasionally reported to produce a higher response rate (RR) than doublets in locally advanced or metastatic non-small-cell lung cancer (NSCLC).
  • This trial was conducted to assess (i) whether the addition of cisplatin (CDDP) to either gemcitabine (GEM) and vinorelbine (VNR) or GEM and paclitaxel (PTX) significantly prolongs overall survival (OS) and (ii) to compare the toxicity of PTX-containing and VNR-containing combinations.
  • PATIENTS AND METHODS: Stage III or IV NSCLC patients were randomly assigned to (i) GEM 1000 mg/m(2) and VNR 25 mg/m(2) on days 1 and 8 (GV arm);.
  • (ii) GEM 1000 mg/m(2) and PTX 125 mg/m(2) on days 1 and 8 (GT arm);.
  • RESULTS: A total of 433 (stage III, 160; stage IV, 273) patients were randomly allocated to the study.


57. Hanada S, Maeshima A, Matsuno Y, Ohta T, Ohki M, Yoshida T, Hayashi Y, Yoshizawa Y, Hirohashi S, Sakamoto M: Expression profile of early lung adenocarcinoma: identification of MRP3 as a molecular marker for early progression. J Pathol; 2008 Sep;216(1):75-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of early lung adenocarcinoma: identification of MRP3 as a molecular marker for early progression.
  • Early lung adenocarcinoma is well-recognized as a small-sized non-invasive adenocarcinoma or localized non-mucinous bronchioloalveolar carcinoma (LNMBAC); however, the molecular events associated with these early lesions are not clear.
  • To determine the genes involved in tumorigenesis at the early stage of lung adenocarcinoma, we compared the mRNA expression profiles of LNMBAC and normal lungs with an oligonucleotide array.
  • Among them, most up-regulated genes, such as AQP3 and Claudin-4, were expressed in both adenocarcinoma cells and type II alveolar pneumocytes, corresponding to the histological similarity between these cell types.
  • However, multidrug resistant protein 3 (MRP3) was only expressed on tumour cell membranes and not in type II alveolar pneumocytes, as confirmed by immunohistochemistry.
  • Moreover, the number of MRP3-positive cells significantly increased from AAH (the precursor lesion of lung adenocarcinoma) to LNMBAC.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Lung Neoplasms / genetics. Multidrug Resistance-Associated Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604784.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Multidrug Resistance-Associated Proteins; 0 / RNA, Neoplasm; 0 / multidrug resistance-associated protein 3
  •  go-up   go-down


58. Woo T, Okudela K, Yazawa T, Wada N, Ogawa N, Ishiwa N, Tajiri M, Rino Y, Kitamura H, Masuda M: Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer; 2009 Sep;65(3):355-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas.
  • The purpose of the present study was to establish accurate prognostic markers to predict the post-operative recurrence of stage I lung adenocarcinomas (ADC).
  • One-hundred and ninety cases of stage I ADC were examined for KRAS mutations and Ki-67 expression, and their associations with disease recurrence were analyzed.
  • Ki-67 high-expressers with KRAS mutations showed an additional higher risk of recurrence compared to low-expressers without mutations (5-year DFS 37.5% vs. 93.3%, P<0.001: adjusted HR 16.82, 95% CI 3.77-74.98, P<0.001) and their 5-year DFS was nearly equivalent to that of stage II non-small cell lung cancer (NSCLC) in our facility (37.5% vs. 37.2% for stage II NSCLC, p=0.577).
  • The combined use of KRAS status and Ki-67 expression level could be an excellent prognostic marker to predict the post-operative recurrence of stage I ADC.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Biomarkers, Tumor / metabolism. Ki-67 Antigen / biosynthesis. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. Mutation. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19162366.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRAS protein, human; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


59. Oshita F, Saito H, Murakami S, Kondo T, Yamada K: Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer. Am J Clin Oncol; 2010 Feb;33(1):66-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer.
  • OBJECTIVES: We conducted a phase II study of combination chemotherapy with paclitaxel (Pac) and irinotecan (CPT) alternating with gefitinib (Gef) to determine the qualitative and quantitative toxicities and efficacy of this combination against advanced non-small-cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: Patients with stage IIIB or IV NSCLC were treated with CPT at 60 mg/m2 and Pac at 160 mg/m2 on day 1 followed by Gef at 250 mg per day on days 8 to 14 every 3 weeks.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19786849.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 7673326042 / irinotecan; P88XT4IS4D / Paclitaxel; S65743JHBS / gefitinib; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


60. Li SY, Liang ZJ, Yuan SJ, Yu B, Chen G, Zuo FY, Bai X, Chen G, Wei XJ, Xu YS, Cui W: [Clinical experience of 371 cases of sphincter-preservation with telescopic anastomosis after radical excision for low-middle rectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Apr;13(4):263-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On histopathology, there were 361 adenocarcinomas, including 138 well-differentiated, 201 moderately differentiated, 11 poorly differentiated, 11 mucinous adenocarcinoma, and 10 adenomas with neoplastic changes.
  • According to the Duke's stage classification, 120 were TNM stage I, 222 stage II, 26 stage III, and 3 stage IV.
  • Hepatic and lung metastasis was 14.5% (46/318) and 2.5% (8/318), respectively.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Anastomosis, Surgical / methods. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422480.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


61. Wang CL, Yue DS, Zhang ZF, Zhan ZL, Sun LN: [Value of thyroid transcription factor-1 in identification of the prognosis of bronchioloalveolar carcinoma]. Zhonghua Yi Xue Za Zhi; 2007 Sep 4;87(33):2350-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Compared with that in the BAC of stage III and that of BAC of non-mucinous type, the CK20 positive rates of the BAC of stage I - II and mucinous type were both significantly higher (chi(2) = 3.928, P < 0.05, and chi(2) = 11.512, P < 0.05).
  • The TTF-1 positive rates of the BAC of stage III and nonmucinous type were significantly higher than those of stage I - II and mucinous type respectively (chi(2) = 7.840, P < 0.05, and chi(2) = 19.497, P < 0.05).
  • Univariate analysis showed that the main prognostic factors were TTF-1 expression (P = 0.017), clinical stage (P = 0.000), tumor diameter (P = 0.017) and N stage (P = 0.000).
  • Strata analysis suggested that in the nonmucinous type BAC patients the survival time of those positive for TTF-1 expression was superior to those negative for TTF-1 (P = 0.009); and in the stage III BAC patients the survival time of those positive for TTF-1 was superior to those negative for TTF-1 (P = 0.022).
  • Cox regression analysis suggested that TTF-1 (P = 0.035), TNM stage (P = 0.000), tumor diameter (P = 0.034), and N stage (P = 0.000) were independent factors affecting the prognosis.
  • TTF-1, TNM stage, tumor diameter and N stage are all independent factors affecting the prognosis of BAC.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Lung Neoplasms / metabolism. Nuclear Proteins / biosynthesis. Transcription Factors / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Keratin-20 / biosynthesis. Keratin-7 / biosynthesis. Lung / chemistry. Lung / pathology. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18036300.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


62. Tibaldi C, Bernardini I, Chella A, Russo F, Vasile E, Malventi M, Falcone A: Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer; 2006 May;7(6):401-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer.
  • PURPOSE: In patients with advanced-stage non-small-cell lung cancer (NSCLC) pretreated with chemotherapy, docetaxel 75 mg/m2 every 3 weeks prolongs survival compared with best supportive care alone or chemotherapy with ifosfamide or vinorelbine.
  • PATIENTS AND METHODS: Thirty-three elderly patients (aged > or = 70 years) with advanced-stage NSCLC, Eastern Cooperative Oncology Group performance status 0-2, and a median age of 74 years (range, 70-83 years) who had progressed after 1 line of chemotherapy were treated with docetaxel 37.5 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 courses.
  • CONCLUSION: Our modified schedule of docetaxel is an active and well-tolerated second-line treatment in elderly patients with advanced-stage NSCLC and has a favorable toxicity profile.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Taxoids / administration & dosage
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Drug Administration Schedule. Female. Health Services for the Aged. Humans. Italy. Male. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800966.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


63. Higashi K, Sakuma T, Ito K, Niho S, Ueda Y, Kobayashi T, Sekiguchi R, Takahashi T, Kato T, Tonami H: Combined evaluation of preoperative FDG uptake on PET, ground-glass opacity area on CT, and serum CEA level: identification of both low and high risk of recurrence in patients with resected T1 lung adenocarcinoma. Eur J Nucl Med Mol Imaging; 2009 Mar;36(3):373-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined evaluation of preoperative FDG uptake on PET, ground-glass opacity area on CT, and serum CEA level: identification of both low and high risk of recurrence in patients with resected T1 lung adenocarcinoma.
  • PURPOSE: Patients with the same pathological stage of lung adenocarcinoma display marked variability in postoperative recurrence.
  • The aim of this study was to predict the postoperative prognosis in patients with small-sized pulmonary adenocarcinoma on the basis of FDG uptake on PET, the extent of ground-glass opacity (GGO) on CT, and serum carcinoembryonic antigen (CEA) levels.
  • METHODS: We evaluated 87 patients (40 men, 47 women; mean age 64 years, age range 42-84 years) with lung adenocarcinoma of 3.0 cm or smaller.
  • RESULTS: The patients were divided into the following four groups: those with the GGO pattern (group I, 13 patients), those with solid pattern and low FDG uptake (group II, 35 patients), those with solid pattern, high FDG uptake, and CEA <20 ng/ml (group III, 32 patients), and those with solid pattern, high FDG uptake, and CEA > or =20 ng/ml (group IV, 7 patients).
  • The 5-year disease-free survival rates were 100% in group I, 80.1% in group II, 43.7% in group III, and 16.7% in group IV (p<0.0001).
  • CONCLUSION: Combined evaluation of preoperative FDG uptake, GGO, and serum CEA level may enable patients with T1 lung adenocarcinoma at low risk and at high risk of postoperative recurrence to be identified.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Lung Neoplasms / diagnostic imaging

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cardiothorac Surg. 2004 May;25(5):877-83 [15082298.001]
  • [Cites] Ann Thorac Surg. 2004 Apr;77(4):1157-61; discussion 1161-2 [15063225.001]
  • [Cites] AJR Am J Roentgenol. 2001 Dec;177(6):1417-22 [11717098.001]
  • [Cites] Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3 [7677489.001]
  • [Cites] Lung Cancer. 2004 Apr;44(1):61-8 [15013584.001]
  • [Cites] J Nucl Med. 2005 Feb;46(2):267-73 [15695786.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2546-54 [12467069.001]
  • [Cites] J Nucl Med. 2004 Apr;45(4):559-66 [15073250.001]
  • [Cites] Eur J Cardiothorac Surg. 2008 May;33(5):819-23 [18374589.001]
  • [Cites] Clin Radiol. 2008 Aug;63(8):856-63 [18625349.001]
  • [Cites] Eur J Nucl Med. 2001 Feb;28(2):155-64 [11303885.001]
  • [Cites] J Nucl Med. 2007 Feb;48(2):214-20 [17268017.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Jun;133(6):1448-54 [17532938.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Jan;135(1):44-9 [18179917.001]
  • [Cites] Radiology. 2001 Sep;220(3):803-9 [11526285.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1136-43 [15718309.001]
  • [Cites] Ann Thorac Surg. 2005 Mar;79(3):984-8; discussion 989 [15734419.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jul;173(1):75-9 [10397103.001]
  • [Cites] J Nucl Med. 1998 Jun;39(6):1016-20 [9627336.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3601-5 [16101187.001]
  • [Cites] J Clin Pathol. 1992 Jul;45(7):591-3 [1517458.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Jun;25(6):1102-6 [15145016.001]
  • [Cites] Lancet Oncol. 2004 Sep;5(9):531-40 [15337482.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Oct;108(4):684-6 [7934103.001]
  • [Cites] AJR Am J Roentgenol. 2004 May;182(5):1129-32 [15100107.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):75-80 [15598942.001]
  • (PMID = 18931837.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


64. Kusumoto S, Hirose T, Fukayama M, Kataoka D, Hamada K, Sugiyama T, Shirai T, Yamaoka T, Okuda K, Ohnishi T, Ohmori T, Kadokura M, Adachi M: Induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer. Oncol Rep; 2009 Nov;22(5):1157-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer.
  • We examined the efficacy and toxicity of a divided schedule of cisplatin and vinorelbine with concurrent radiotherapy followed by surgery in patients with locally advanced non-small cell lung cancer (NSCLC).
  • Patients with clinical stage IIIA or IIIB NSCLC were eligible if they had a performance status of 0 or 1, were 75 years or younger, and had adequate organ function.
  • The median survival time was 36 months (range, 4-78 months), the 2-year survival rate was 74%, and the median time to disease progression was 15 months (range, 2-59 months).
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Squamous Cell / therapy. Lung Neoplasms / therapy


65. Shanmugam C, Jhala NC, Katkoori VR, Wan W, Meleth S, Grizzle WE, Manne U: Prognostic value of mucin 4 expression in colorectal adenocarcinomas. Cancer; 2010 Aug 01;116(15):3577-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients who had early stage tumors (stages I and II) with high MUC4 expression had a shorter disease-specific survival (log-rank; P=.007) than patients who had with low expression.
  • Patients who had advanced-stage CRCs (stages III and IV) did not demonstrate such a difference (log-rank; P=.108).
  • Multivariate regression models that were generated separately for patients with early stage and advanced-stage CRC confirmed that increased expression of MUC4 was an independent indicator of a poor prognosis only for patients who had early stage CRCs (hazard ratio, 3.77; 95% confidence interval, 1.46-9.73).
  • CONCLUSIONS: The current results indicated that increased MUC4 expression is a predictor of poor survival in CRC, specifically for patients who have early stage tumors.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colorectal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Cancer Society.
  • [Cites] Gastroenterology. 1994 Apr;106(4):1054-61 [8143972.001]
  • [Cites] Cancer Res. 1992 Nov 1;52(21):5971-8 [1394223.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1054-9 [8683636.001]
  • [Cites] J Clin Pathol. 1996 Jul;49(7):560-4 [8813954.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):346-58 [9221816.001]
  • [Cites] J Histochem Cytochem. 1999 Aug;47(8):1063-74 [10424891.001]
  • [Cites] Cancer. 2005 May 15;103(10):2163-70 [15816050.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):806-13 [15897748.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):881-9 [15958852.001]
  • [Cites] J Clin Pathol. 2005 Aug;58(8):845-52 [16049287.001]
  • [Cites] Prostate. 2006 Mar 1;66(4):421-9 [16302265.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4257-64 [16857800.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1386-94 [16880776.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):572-9 [17019794.001]
  • [Cites] Lung Cancer. 2007 Feb;55(2):195-203 [17126950.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):433-6 [17234748.001]
  • [Cites] Arch Pathol Lab Med. 2007 Apr;131(4):593-8 [17425390.001]
  • [Cites] Mol Cancer Res. 2007 Apr;5(4):309-20 [17406026.001]
  • [Cites] Eur J Clin Invest. 2007 May;37(5):416-24 [17461988.001]
  • [Cites] Br J Cancer. 2007 Aug 6;97(3):345-57 [17595659.001]
  • [Cites] J Histochem Cytochem. 2008 Mar;56(3):305-12 [18071066.001]
  • [Cites] FASEB J. 2008 Apr;22(4):966-81 [18024835.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2065-70 [18381409.001]
  • [Cites] Eur J Cancer. 2008 May;44(7):1048-56 [18397823.001]
  • [Cites] FASEB J. 2008 Aug;22(8):3035-45 [18492726.001]
  • [Cites] Oncol Rep. 2009 Jan;21(1):49-56 [19082442.001]
  • [Cites] Br J Cancer. 2009 Jan 27;100(2):344-51 [19127263.001]
  • [Cites] Dig Dis. 1999;17(2):67-79 [10545712.001]
  • [Cites] Histopathology. 2000 Feb;36(2):121-6 [10672056.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4017-25 [11051251.001]
  • [Cites] Oncogene. 2001 Jan 25;20(4):461-70 [11313977.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4033-40 [11751498.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] J Histochem Cytochem. 2004 Feb;52(2):253-61 [14729877.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):150-7 [14657954.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] Head Neck. 2004 Apr;26(4):353-64 [15054739.001]
  • [Cites] Laryngoscope. 2004 Aug;114(8 Pt 2 Suppl 101):1-32 [15284539.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1633-8 [15494719.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):953-64 [7657125.001]
  • (PMID = 20564074.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U54 CA118623; United States / NCI NIH HHS / CA / U54 CA118948; United States / NCI NIH HHS / CA / 2U54-CA118948-03; United States / NCI NIH HHS / CA / R01 CA098932; United States / NCI NIH HHS / CA / U24-CA086359; United States / NCI NIH HHS / CA / R01-CA98932-01; United States / NCI NIH HHS / CA / R03-CA139629-01; United States / NCI NIH HHS / CA / R03 CA139629; United States / NCI NIH HHS / CA / R03 CA139629-01; United States / NCI NIH HHS / CA / U24 CA086359
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucin-4
  • [Other-IDs] NLM/ NIHMS189749; NLM/ PMC2910814
  •  go-up   go-down


66. Mack PC, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y, Beckett LA, Lara PN Jr, Davies AM, Gandara DR: EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol; 2009 Dec;4(12):1466-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
  • PURPOSE: Activating mutations in the epidermal growth factor receptor (EGFR) are associated with enhanced response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC), whereas KRAS mutations translate into poor patient outcomes.
  • METHODS: An allele-specific polymerase chain reaction assay using Scorpion-amplification refractory mutation system (DxS, Ltd) was used to detect mutations in plasma DNA from patients with advanced stage NSCLC treated as second- or third-line therapy on a phase I/II trial of docetaxel plus intercalated erlotinib.
  • Four of 49 patients harbored a de novo T790M resistance mutation (median progression-free survival, 3.9 months).

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19884861.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA093373; United States / NCI NIH HHS / CA / P30 CA93373
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Quinazolines; 0 / Taxoids; 15H5577CQD / docetaxel; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


67. Seki N, Eguchi K, Kaneko M, Ohmatsu H, Kakinuma R, Matsui E, Kusumoto M, Tsuchida T, Nishiyama H, Moriyama N: The adenocarcinoma-specific stage shift in the Anti-lung Cancer Association project: significance of repeated screening for lung cancer for more than 5 years with low-dose helical computed tomography in a high-risk cohort. Lung Cancer; 2010 Mar;67(3):318-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The adenocarcinoma-specific stage shift in the Anti-lung Cancer Association project: significance of repeated screening for lung cancer for more than 5 years with low-dose helical computed tomography in a high-risk cohort.
  • BACKGROUND: We investigated whether a stage shift occurs during long-term repeated screening for lung cancer with low-dose helical computed tomography (LDCT) in a high-risk cohort.
  • RESULTS: Nineteen lung cancers were detected at baseline examinations (prevalence cancers), and 57 lung cancers were detected at subsequent examinations (incidence cancers).
  • For both prevalence cancers and incidence cancers, adenocarcinoma (74% and 63%, respectively), especially invasive adenocarcinoma (42% and 23%, respectively), was the most common histological diagnosis, and stage IA was the most common pathological stage (58% and 79%, respectively).
  • Moreover, both the percentage of cancers of stage II-IV and tumor size became significantly lower for invasive adenocarcinoma after 5 years of LDCT examinations (r=-0.77, P=0.007 and r=-0.60, P=0.029, respectively).
  • CONCLUSIONS: Repeated screening for more than 5 years might demonstrate the efficacy of LDCT screening for lung cancer through an adenocarcinoma-specific stage shift.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / radiography. Lung Neoplasms / epidemiology. Lung Neoplasms / radiography

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19481832.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


68. Davies AM, Chansky K, Lara PN Jr, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR, Southwest Oncology Group: Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol; 2009 Jan;4(1):87-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
  • INTRODUCTION: Bortezomib is a small-molecule proteasome inhibitor with single-agent activity in patients with non-small cell lung carcinoma (NSCLC) and synergy with gemcitabine in preclinical studies.
  • This phase II study of bortezomib in combination with gemcitabine/carboplatin was conducted in chemotherapy-naive advanced NSCLC patients to assess efficacy and safety.
  • METHODS: Patients with selected stage IIIB/IV NSCLC, performance status 0-1, and no history of brain metastasis received up to six 21-day cycles of gemcitabine 1000 mg/m, days 1 and 8, carboplatin area under curve 5.0, day 1, and bortezomib 1.0 mg/m, days 1, 4, 8, and 11.
  • RESULTS: One-hundred-fourteen patients (52% adenocarcinoma, 85% stage IV) received a median of 3.6 treatment cycles.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Adult. Aged. Boronic Acids / administration & dosage. Bortezomib. Carboplatin / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Cohort Studies. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Pyrazines / administration & dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3210-8 [11432888.001]
  • [Cites] J Surg Res. 2001 Sep;100(1):11-7 [11516199.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Lung Cancer. 2002 Jul;37(1):9-14 [12057861.001]
  • [Cites] Oncologist. 2002;7(3):226-33 [12065795.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2505-11 [12171876.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4285-91 [12409326.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1145-54 [12631620.001]
  • [Cites] Lung Cancer. 2003 Jul;41(1):81-9 [12826316.001]
  • [Cites] Lung Cancer. 2003 Aug;41 Suppl 1:S89-96 [12867067.001]
  • [Cites] Lung Cancer. 2003 Sep;41(3):321-31 [12928123.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):33714-23 [12821677.001]
  • [Cites] Cancer Sci. 2004 Feb;95(2):176-80 [14965369.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5022-6 [15297403.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Oct;54(4):343-53 [15197486.001]
  • [Cites] Oncology (Williston Park). 2004 Jul;18(8 Suppl 5):13-20 [15339054.001]
  • [Cites] Oncology (Williston Park). 2004 Jul;18(8 Suppl 5):21-6 [15339055.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2004 Spring;16(1):28-39 [15366685.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1207-14; discussion 1207-14 [15464472.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):190-6 [15625373.001]
  • [Cites] Clin Lung Cancer. 2004 Dec;6 Suppl 2:S89-96 [15638966.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3777-84 [16099887.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9097-104 [16361616.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Jun;58(3):177-89 [16427303.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3113-20 [16754936.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):781-92 [16847887.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5025-33 [17075122.001]
  • [Cites] Oncology (Williston Park). 2006 Nov;20(12):1515-24; discussion 1524-5, 1530, 1535 [17153906.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):317-23 [17079694.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):68-74 [18166843.001]
  • (PMID = 19096312.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA86780; United States / NCI NIH HHS / CA / U10 CA027057; United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / U10 CA035128; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / U10 CA063850; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / CA35281; United States / NCI NIH HHS / CA / N01 CA045807; United States / NCI NIH HHS / CA / U10 CA032102-32; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / U10 CA180846; United States / NCI NIH HHS / CA / N01 CA046441; United States / NCI NIH HHS / CA / CA58882; United States / NCI NIH HHS / CA / U10 CA035281; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / N01 CA063844; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / U10 CA035178; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / N01 CA035178; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / N01 CA027057; United States / NCI NIH HHS / CA / U10 CA046441; United States / NCI NIH HHS / CA / U10 CA058882; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / U10 CA086780; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / U10 CA046368; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / U10 CA063844; United States / NCI NIH HHS / CA / U10 CA045807; United States / NCI NIH HHS / CA / N01 CA045560
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 0W860991D6 / Deoxycytidine; 69G8BD63PP / Bortezomib; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ NIHMS244778; NLM/ PMC3024911
  •  go-up   go-down


69. Kasprzyk M, Dyszkiewicz W, Zwaruń D, Leśniewska K, Wiktorowicz K: [The assessment of acute phase proteins as prognostic factors in patients surgically treated for non-small cell lung cancer]. Pneumonol Alergol Pol; 2008;76(5):321-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The assessment of acute phase proteins as prognostic factors in patients surgically treated for non-small cell lung cancer].
  • INTRODUCTION: The aim of the study was to assess quantitative changes of the acute phase protein (APP) serum level in patients with non-small cell lung cancer (NSCLC) who underwent a radical resection.
  • We analysed the correlation between quantitative APP changes and: the survival rate, the histological type of the cancer, TNM stage and grading.
  • The most frequent histological types of cancer were: squamous cell lung cancer (24 patients) and adenocarcinoma (17 patients).
  • The majority of them were in stage II B (15 patients) and III A (14 patients).
  • RESULTS: The level of AT was significantly higher in patients with adenocarcinoma, as compared to other histological types of cancer.
  • In the case of patients with squamous cell lung cancer, significantly higher M and Cp.
  • The multivariate analysis confirmed the influence of the following factors on long-term survival: N stage, histological type of cancer and preoperative serum levels of AGP and Hp.
  • CONCLUSIONS: The serum concentration of some APP may correlate with the more aggressive clinical behavior of lung cancer.
  • The patients with N1 or N2 stage of adenocarcinoma have significantly higher serum level of AT and the preoperative concentration of AGP and Hp correlates with the overall survival.
  • [MeSH-major] Acute-Phase Proteins / analysis. Adenocarcinoma / blood. Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Squamous Cell / blood. Lung Neoplasms / blood


70. Zhang Z, Chen Y, Chen Y, Jeter M, Hofstetter WL, Ajani J, Swisher SG, Chang JY, Allen PK, Cox JD, Komaki R, Liao ZX: Outcomes with esophageal cancer radiation therapy. J Thorac Oncol; 2009 Jul;4(7):880-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Men make up 75% or more of the patients with esophageal cancer, most patients have adenocarcinoma in the gastroesophageal junction, and almost 75% have stage II or III disease.
  • CONCLUSION: Although fully delineated comparisons must await incorporation and study of data through 2007, this analysis suggests that multimodality management that has been adapted in recent years may be associated with the improvements in outcomes of these cases of largely stage II and III esophageal adenocarcinoma found at the gastroesophageal junction.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19458557.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Gallegos Ruiz MI, Floor K, Roepman P, Rodriguez JA, Meijer GA, Mooi WJ, Jassem E, Niklinski J, Muley T, van Zandwijk N, Smit EF, Beebe K, Neckers L, Ylstra B, Giaccone G: Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One; 2008;3(3):e0001722
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target.
  • BACKGROUND: Lung cancer causes approximately 1.2 million deaths per year worldwide, and non-small cell lung cancer (NSCLC) represents 85% of all lung cancers.
  • Understanding the molecular events in non-small cell lung cancer (NSCLC) is essential to improve early diagnosis and treatment for this disease.
  • METHODOLOGY AND PRINCIPAL FINDINGS: In an attempt to identify novel NSCLC related genes, we performed a genome-wide screening of chromosomal copy number changes affecting gene expression using microarray based comparative genomic hybridization and gene expression arrays on 32 radically resected tumor samples from stage I and II NSCLC patients.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Gene Dosage. Gene Expression Regulation, Neoplastic. HSP90 Heat-Shock Proteins / genetics. Lung Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / secondary. Chromosome Aberrations. Chromosomes, Human, Pair 14 / genetics. Female. Follow-Up Studies. Genome, Human. Humans. Male. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Tumor Cells, Cultured


72. Niang A, Bonnichon A, Ba-Fall K, Dussart C, Camara P, Vaylet F, Mbaye PS, L'Her P, Sane M, Margery J: [Lung cancer in Senegal]. Med Trop (Mars); 2007 Dec;67(6):651-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung cancer in Senegal].
  • In Africa the incidence of lung cancer is rising rapidly.
  • The purpose of this prospective study was to analyze clinical, therapeutic, and prognostic features of lung cancer patients treated at the Principal Hospital in Dakar between 2002 and 2007.
  • The histological diagnosis was squamous cell carcinoma in 23 cases, adenocarcinoma in 14, large-cell carcinoma in 17, small-cell lung cancer in 2, and bronchiolo-alveolar cancer in 1.
  • Tumor staging demonstrated grades I-II in 6 cases, grade II in 17, and grade IV in 49.
  • Prognosis of the disease is poor because management is undertaken at an advanced stage.
  • Lung cancer is a health issue in Dakar, Senegal.
  • [MeSH-major] Carcinoma / epidemiology. Carcinoma / therapy. Lung Neoplasms / epidemiology. Lung Neoplasms / therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300532.001).
  • [ISSN] 0025-682X
  • [Journal-full-title] Médecine tropicale : revue du Corps de santé colonial
  • [ISO-abbreviation] Med Trop (Mars)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


73. Wislez M, Antoine M, Baudrin L, Poulot V, Neuville A, Pradere M, Longchampt E, Isaac-Sibille S, Lebitasy MP, Cadranel J: Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer; 2010 May;68(2):185-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.
  • There is no optimal established therapy for treating advanced or recurrent adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC), and it remains unclear whether chemotherapy achieves therapeutic results comparable to those seen in the more common non-small lung carcinoma subtypes.
  • Fifty pathological samples were obtained from 62 patients included in a multicenter prospective phase II trial (IFCT0401) conducted to evaluate gefitinib as a first-line therapy for non-resectable ADC-BAC.
  • We demonstrated that demographic data, clinical characteristics and stage at presentation (extrathoracic versus lung metastasis, as well as TNM staging) did not distinguish between the two subtypes.
  • In contrast, three biological markers (PAS staining, TTF-1 expression and EGFR genomic gain combined with mutation analysis) enabled us to independently segregate all but 2 of the 50 patients into the mucinous and non-mucinous ADC-BAC subtypes.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnosis. Adenocarcinoma, Mucinous / diagnosis. DNA-Binding Proteins / metabolism. Lung Neoplasms / diagnosis. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19581016.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Quinazolines; 0 / TTF1 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


74. Riquet M, Foucault C, Berna P, Assouad J, Dujon A, Danel C: Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping. Ann Thorac Surg; 2006 Jun;81(6):1988-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping.
  • BACKGROUND: Adenocarcinoma (AC) is the most common lung cancer, followed by squamous cell carcinoma (SCC).
  • Therefore, we compared subgroups according to presence or not of bronchioloalveolar carcinoma or solid adenocarcinoma with mucin component, or both.
  • RESULTS: Compared with ACs, SCCs had a higher number of males and older patients, and incidences of endobronchial tumors, pneumonectomies, and stage II tumors were higher.
  • The ACs with solid AC with mucin components (n = 239) were characterized by more males and stage IIB patients, and had poorer survival rates (38.6% vs 61.4%; p < 0.0014) than the ACs without solid AC with mucin component.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / mortality. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Adenocarcinoma, Bronchiolo-Alveolar / therapy. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / therapy. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant / statistics & numerical data. Combined Modality Therapy. Female. Humans. Life Tables. Male. Middle Aged. Neoplasm Staging. Pneumonectomy / methods. Pneumonectomy / statistics & numerical data. Prognosis. Radiotherapy, Adjuvant / statistics & numerical data. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731118.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


75. Chang JW, Asamura H, Kawachi R, Watanabe S: Gender difference in survival of resected non-small cell lung cancer: histology-related phenomenon? J Thorac Cardiovasc Surg; 2009 Apr;137(4):807-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender difference in survival of resected non-small cell lung cancer: histology-related phenomenon?
  • OBJECTIVE: It remains controversial whether there is a gender difference in survival of patients with resected non-small cell lung cancer.
  • METHODS: We retrospectively analyzed 2770 patients (1689 men and 1081 women) with non-small cell lung cancer who underwent pulmonary resection between 1995 and 2005 at the National Cancer Center Hospital, Tokyo.
  • A gender difference in survival was studied in all patients, in those divided according to histology or pathologic stage, and in propensity-matched gender pairs.
  • The proportions of adenocarcinoma and pathologic stage I in women were greater than those in men (93.6% vs 61.7% and 71.4% vs 58.6%, respectively) (P < .001).
  • In adenocarcinoma, the overall 5-year survival for women was better than that for men in pathologic stage I (95% vs 87%, P < .001) and in pathologic stage II or higher (58% vs 51%, P = .017).
  • In non-adenocarcinoma, there was no significant gender difference in survival in pathologic stage I (P = .313) or pathologic stage II or higher (P = .770).
  • The variables such as age, smoking status, histology, and pathologic stage were used for propensity score matching, and survival analysis of propensity score-matched gender pairs did not show a significant difference (P = .69).
  • A gender difference in survival was observed only in the adenocarcinoma subset, suggesting pathobiology in adenocarcinoma in women might be different from that of men.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / mortality. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19327500.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Belani CP, Schreeder MT, Steis RG, Guidice RA, Marsland TA, Butler EH, Ramalingam SS: Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer; 2008 Nov 01;113(9):2512-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study.
  • BACKGROUND: Cetuximab, an immunoglobulin (Ig) G1 chimeric monoclonal antibody against the epidermal growth factor receptor, has demonstrated evidence of activity in nonsmall cell lung cancer (NSCLC).
  • METHODS: Chemotherapy-naïve patients aged >or=18 years with stage IIIB (with effusion) or stage IV NSCLC received cetuximab (at a dose of 400 mg/m(2) on Day 1 and 250 mg/m(2) on Days 8 and 15) plus docetaxel (at a dose of 75 mg/m(2) on Day 1) and carboplatin (area under the concentration vs time curve [AUC]=6 on Day 1) every 21 days for up to 6 cycles (graded according to the American Joint Committee on Cancer Staging System).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Carboplatin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Cetuximab. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Middle Aged. Prognosis. Remission Induction. Survival Rate. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18816622.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA180864
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; PQX0D8J21J / Cetuximab
  •  go-up   go-down


77. Lee DH, Han JY, Lee HG, Lee JJ, Lee EK, Kim HY, Kim HK, Hong EK, Lee JS: Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res; 2005 Apr 15;11(8):3032-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.
  • PURPOSE: A subset of patients with adenocarcinoma of the lung who had never smoked cigarettes showed excellent tumor responses to gefitinib therapy.
  • To evaluate the efficacy of gefitinib as a first-line therapy in this subgroup of patients, we conducted a phase II study.
  • EXPERIMENTAL DESIGN: Eligible patients had no smoking history, stage IIIB or IV adenocarcinoma, Eastern Cooperative Oncology Group performance status 0 to 2, and adequate organ functions.
  • CONCLUSIONS: Gefitinib showed very dramatic antitumor activity, even in the brain, with unprecedented survival outcome in never-smoker adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837758.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


78. Wang J, Kuo YF, Freeman J, Markowitz AB, Goodwin JS: Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer. Cancer; 2008 Jan 15;112(2):382-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer.
  • BACKGROUND: The authors assessed patterns of perioperative chemotherapy use in elderly patients with resected stage I, II, or IIIA nonsmall cell lung cancer (NSCLC) from 1992 to 2002.
  • METHODS: By using data from the Surveillance, Epidemiology, and End Results Program, 11,807 patients were identified who had resected stage I, II, or IIIA NSCLC between 1992 and 2002 and survived >or=120 days beyond diagnosis.
  • RESULTS: In total, 957 patients with stage I, II, or IIIA NSCLC (8.1% of the study population) received perioperative chemotherapy.
  • The proportion of patients receiving chemotherapy for stage I NSCLC changed little during the study period.
  • Of 3230 patients with stage II and IIIA NSCLC, 609 patients (18.9%) received chemotherapy, 423 patients (13%) received chemotherapy combined with radiation.
  • Younger age, being married, having advanced-stage tumor or adenocarcinoma, having a later diagnosis year, receiving radiation, and seeing an oncologist were predictors for the receipt of chemotherapy (P< .001).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy


79. Yang L, Liu XY, Fang J, An TT, Wu MN: [Gefitinib in the treatment of advanced non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2006 Jun;28(6):474-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gefitinib in the treatment of advanced non-small cell lung cancer].
  • OBJECTIVE: To investigate the efficacy, time to progression, survival time and toxicity of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor Gefitinib (Iressa), a target therapy agent, in the treatment of advanced non-small cell lung cancer (NSCLC), and to analyze the factors affecting the efficacy and patients' survival.
  • Seventy-six (83.5%) of the 91 patients had stage IV disease, and 42 (46.2%) had developed metastases at least two sites.
  • The disease control rate of those who had adenocarcinoma, or received second-line chemotherapy or developed skin toxicity was significantly better than the other patients (P value = 0.04, 0.02, 0.00, respectively). (2) Median time to progress (TIP) was 5.0 months (95% CI 3.26-6.74). (3) Median following-up duration was 7.5 months (1-18.
  • Non-smoker, stable diseases, skin toxicities, and controlled metastatic diseases during the treatment of gefitinib were the favorable factors affecting the survival (P value = 0.00, 0.00, 0.00, 0.01, respectively). (4) The main toxicity of gefitinib was grade I or II skin toxicity.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use


80. D'Angelillo RM, Trodella L, Ciresa M, Cellini F, Fiore M, Greco C, Pompeo E, Mineo TC, Paleari L, Granone P, Ramella S, Cesario A: Multimodality treatment of stage III non-small cell lung cancer: analysis of a phase II trial using preoperative cisplatin and gemcitabine with concurrent radiotherapy. J Thorac Oncol; 2009 Dec;4(12):1517-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality treatment of stage III non-small cell lung cancer: analysis of a phase II trial using preoperative cisplatin and gemcitabine with concurrent radiotherapy.
  • INTRODUCTION: We report the results of a phase II trial exploring the efficacy and the feasibility of combination of gemcitabine and cisplatin concurrent with radiotherapy followed by surgery in patients with stage III non-small cell lung cancer.
  • METHODS: Patients with histocytologically confirmed non-small cell lung cancer were treated with cisplatin 80 mg/sqm/wk of 1 and 4 or 20 mg/sqm/d of weeks 1 and 4 and weekly gemcitabine at 300 to 350 mg/m2 plus involved field radiotherapy.
  • RESULTS: The stage at diagnosis was IIIA-N2 in 29 patients and IIIB-T4N0-2 for vascular direct infiltration for the remaining 21.
  • Final pathology showed a downstaging to stage 0 to I in 25 cases (50%).
  • CONCLUSIONS: The results of this phase II trial confirm the feasibility and the efficacy of concurrent chemoradiotherapy followed by surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / radiotherapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dose Fractionation. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19875976.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


81. Detterbeck FC, Socinski MA, Gralla RJ, Edelman MJ, Jahan TM, Loesch DM, Limentani SA, Govindan R, Zaman MB, Ye Z, Monberg MJ, Obasaju CK: Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer. J Thorac Oncol; 2008 Jan;3(1):37-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer.
  • BACKGROUND: Surgical resection alone remains suboptimal for patients with early-stage (I or II) non-small cell lung cancer.
  • Two similar randomized phase II trials were conducted to define an active preoperative regimen in this disease state.
  • The confirmed pCR rate was 2.3% (2 of 87, 95% confidence interval 0.3-8.1).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Cisplatin / administration & dosage. Drug Administration Schedule. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166839.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


82. Shivapurkar N, Stastny V, Suzuki M, Wistuba II, Li L, Zheng Y, Feng Z, Hol B, Prinsen C, Thunnissen FB, Gazdar AF: Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett; 2007 Mar 8;247(1):56-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of a methylation gene panel by quantitative PCR for lung cancers.
  • Detection of lung cancer at early stages could potentially increase survival rates.
  • One promising approach is the application of suitable lung cancer-specific biomarkers to specimens obtained by non-invasive methods.
  • Using quantitative real time PCR, we tested 11 genes (3-OST-2, RASSF1A, DcR1, DcR2, P16, DAPK, APC, ECAD, HCAD, SOCS1, SOCS3) for levels of methylation within their promoter sequences in non-small cell lung cancers (NSCLC), adjacent non-malignant lung tissues, in peripheral blood mononuclear cells (PBMC) from cancer free patients, in sputum of cancer patients and controls.
  • 3-OST-2 followed by, RASSF1A showed increased levels of methylation with advanced tumor stage (P<0.05).

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Top Microbiol Immunol. 2000;249:35-54 [10802937.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6493-8 [10829066.001]
  • [Cites] Annu Rev Biochem. 1999;68:729-77 [10872465.001]
  • [Cites] J Cell Sci. 2000 Aug;113 ( Pt 16):2813-9 [10910765.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4366-71 [10969779.001]
  • [Cites] Bioessays. 2001 Apr;23(4):352-8 [11268041.001]
  • [Cites] Oncogene. 2001 Jun 14;20(27):3528-32 [11429699.001]
  • [Cites] Br J Radiol. 2001 Jun;74(882):478-85 [11459725.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):83S-86S [11560979.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):371-5 [11809682.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):210-9 [11990857.001]
  • [Cites] Annu Rev Biochem. 2002;71:435-71 [12045103.001]
  • [Cites] Cytometry. 2002 Jun 15;50(3):168-76 [12116340.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):629-34 [12163387.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]
  • [Cites] Eur Respir J. 2002 Aug;20(2):464-79 [12212983.001]
  • [Cites] Oncogene. 2003 Jan 16;22(2):274-80 [12527896.001]
  • [Cites] Nat Cell Biol. 2003 Mar;5(3):190-2 [12646874.001]
  • [Cites] Histol Histopathol. 2003 Apr;18(2):665-77 [12647816.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1370-5 [12684406.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3034-41 [12912953.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14133-8 [14617776.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):786-92 [14999791.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2284-8 [15073103.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2928-35 [15131027.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3757-60 [15172980.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4244-50 [15205337.001]
  • [Cites] Clin Lung Cancer. 2004 May;5(6):366-70 [15217536.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):619-27 [8573335.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1197-206 [9508208.001]
  • [Cites] Curr Opin Cell Biol. 1999 Apr;11(2):255-60 [10209153.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 21;91(8):675-90 [10218505.001]
  • [Cites] Oncogene. 2005 Jan 20;24(4):732-6 [15580314.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):656-60 [15825171.001]
  • (PMID = 16644104.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA096109; United States / NCI NIH HHS / CA / P50 CA070907-079001; United States / NCI NIH HHS / CA / CA070907-070003; United States / NCI NIH HHS / CA / P50 CA70907; United States / NCI NIH HHS / CA / CA070907-060003; United States / NCI NIH HHS / CA / P50 CA070907-060003; United States / NCI NIH HHS / CA / U01 CA084971; United States / NCI NIH HHS / CA / P50 CA070907-070003; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / P50 CA070907-069001; United States / NCI NIH HHS / CA / P01 CA096964; United States / NCI NIH HHS / CA / CA070907-079001; United States / NCI NIH HHS / CA / CA070907-069001
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS191864; NLM/ PMC3379713
  •  go-up   go-down


83. Lee DH, Han JY, Cho KH, Pyo HR, Kim HY, Yoon SJ, Lee JS: Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys; 2005 Nov 15;63(4):1037-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.
  • PURPOSE: For locoregionally advanced inoperable non-small-cell lung cancer (NSCLC), concurrent chemoradiotherapy has become a standard therapy.
  • We conducted a Phase II trial to examine the efficacy and toxicity of adding gemcitabine and vinorelbine induction chemotherapy to concurrent chemoradiotherapy with oral etoposide and cisplatin.
  • METHODS AND MATERIALS: Eligibility included inoperable clinical Stage III NSCLC without pleural effusion, ECOG performance status 0-1, and weight loss < or =5%.
  • The median age was 59 years and 13 patients had IIIA and 27 had IIIB; 24 had squamous ca, 12 had adenocarcinoma, and 4 had others.
  • CONCLUSIONS: Induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with etoposide and cisplatin showed very promising survival in patients with Stage III NSCLC, especially in those without supraclavicular nodal involvement, which warrants further evaluation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024178.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


84. Chen PC, Zhou XM, Chen QX, Liu JS, Yan FL, Jiang YH: [Sleeve resection for lung cancer: a report of 82 cases]. Ai Zheng; 2008 May;27(5):510-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sleeve resection for lung cancer: a report of 82 cases].
  • BACKGROUND & OBJECTIVE: Bronchial sleeve resection and/or pulmovascular sleeve resection can maximize preservation of normal lung tissues after tumor resection, which provides a resection mode for lung cancer surgery.
  • This study was to investigate the technique, operative results and survival of lung cancer patients after sleeve resection.
  • METHODS: Eighty-two central lung cancer patients underwent sleeve resection in Zhejiang Cancer Hospital from Jun.
  • Of the 82 patients, 49 (59.8%) were at stage N1, 21 (25.6%) at stage N2.
  • The differences in 1-, 3-, and 5-year survival rates among N1(-) N2(-), N1 (+) N2(-), N2(+) patients, and among stageI, II, IIIA, IIIB patients were significant (P<0.01).
  • CONCLUSIONS: Perioperative mortality and the incidence of anastomosis-related complications for lung cancer patients after sleeve resection are low.
  • The survival of lung cancer patients after sleeve resection is conelated to lymph node metastasis and clinical stage, but has no correlation to gender or age.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Lymph Node Excision / methods. Pneumonectomy / methods
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Postoperative Complications. Survival Rate


85. Carretta A, Ciriaco P, Melloni G, Bandiera A, Libretti L, Puglisi A, Giovanardi M, Zannini P: Surgical treatment of multiple primary adenocarcinomas of the lung. Thorac Cardiovasc Surg; 2009 Feb;57(1):30-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of multiple primary adenocarcinomas of the lung.
  • INTRODUCTION: The incidence of lung adenocarcinomas has steadily increased over the last decades.
  • The aim of this study was to assess the results of surgical treatment of multiple primary adenocarcinomas of the lung (MPAL) analyzing the radiological and histological features.
  • Patients with stage II and III a tumors had significantly reduced survival rates ( P < 0.05).
  • [MeSH-major] Adenocarcinoma / surgery. Lung Neoplasms / surgery. Neoplasms, Multiple Primary. Pneumonectomy. Thoracic Surgery, Video-Assisted. Thoracotomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169994.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


86. Belderbos JS, Heemsbergen WD, De Jaeger K, Baas P, Lebesque JV: Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys; 2006 Sep 1;66(1):126-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy.
  • PURPOSE: The aim of this study was to determine the maximum tolerated dose (MTD) delivered within 6 weeks in patients with non-small-cell lung cancer (NSCLC).
  • METHODS AND MATERIALS: A Phase I/II trial was performed including inoperable NSCLC patients.
  • According to the relative mean lung dose (rMLD), five risk groups with different starting doses were defined: Group 1, rMLD 0.0 to 0.12; Group 2, rMLD 0.12 to 0.18; Group 3, rMLD 0.18 to 0.24; Group 4, rMLD 0.24 to 0.31; and Group 5, rMLD 0.31 to 0.40.
  • Tumor Stage I or II was found in 53%, IIIA in 31%, and IIIB in 17%.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Lung Neoplasms / radiotherapy. Radiotherapy, Conformal / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16904518.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Mylonakis N, Athanasiou A, Ziras N, Angel J, Rapti A, Lampaki S, Politis N, Karanikas C, Kosmas C: Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer; 2010 May;68(2):240-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer.
  • In the present randomized phase II study, we examined the efficacy and safety of a Lipoplatin-gemcitabine versus a cisplatin-gemcitabine combination as first line treatment in advanced NSCLC.
  • A preliminary efficacy of LipoGem versus CisGem in the adenocarcinoma histological subtype of NSCLC showed 16.7% versus 45.8% PD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / administration & dosage. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19628292.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / lipoplatin; 0W860991D6 / Deoxycytidine; AYI8EX34EU / Creatinine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


88. Wakelee HA, Bernardo P, Johnson DH, Schiller JH: Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer; 2006 May 15;106(10):2208-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
  • BACKGROUND: Demographic factors and treatment regimens were evaluated in relation to differences in outcome between patients with advanced nonsmall cell lung cancer (NSCLC) who were diagnosed and treated on Eastern Cooperative Oncology Group Phase II and III trials from 1981 to 1990 and from 1991 to 2000.
  • RESULTS: Patients who entered on trials after 1990 more likely were women, received a cisplatin-containing regimen, had a performance status of 0 or 1, had Stage IIIB (vs. Stage IV) disease, had tumors with adenocarcinoma histology, had weight loss < or = 10%, and had pulmonary-only metastases (although more total metastases and brain metastases) compared with patients who were diagnosed before 1990.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Salvage Therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Chi-Square Distribution. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Probability. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society
  • (PMID = 16604529.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-23318
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


89. Kaira K, Takise A, Minato K, Iwasaki Y, Ishihara S, Takei Y, Tsuchiya S, Saito R, Sato K, Mori M: Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer. Anticancer Drugs; 2005 Apr;16(4):455-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer.
  • We conducted a phase II study to examine the efficacy and safety of weekly docetaxel and cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC).
  • Forty chemotherapy-naive patients (10 with stage IIIB and 30 with stage IV NSCLC) with an Eastern Cooperative Oncology Group performance status of 0-2 and adequate organ functions were enrolled.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Cisplatin / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Survival Rate. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746583.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


90. Zhou ZW, Wan DS, Wang GQ, Ren JQ, Lu ZH, Lin SX, Tang SX, Ye YL, Chen G: [Inhibitory effect of angiogenesis inhibitor YH-16 on liver metastases from colorectal cancer]. Ai Zheng; 2006 Jul;25(7):818-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: YH-16, a new recombinant angiogenesis inhibitor, has demonstrated synergetic effects with chemotherapy in non-small-cell lung cancer treatment in stage II clinical trial.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Animals. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Endothelial Cells / cytology. Female. Inhibitory Concentration 50. Mice. Mice, Inbred BALB C. Microvessels / pathology. Random Allocation. Tumor Burden / drug effects

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831270.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Endostatins; 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A, mouse
  •  go-up   go-down


91. Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K: Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest; 2008 May;26(4):344-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
  • However, the clinical significance of the expression of MDR-related proteins p-glycoprotein (PGP), glutathione-s-transferases (GST-pi), topoisomerase-II (Topo-II) and lung resistance protein (LRP) in primary gastric cardiac adenocarcinoma (PGCA) remains unclear.
  • The expression of PGP, GST-pi, Topo-II and LRP in formalin-fixed paraffin-embedded tissue sections was determined by a labelled streptavidin-biotin immunohistochemical technique, and the results were analyzed in correlation with clinicopathological data.
  • RESULTS: The positive rates of expression of PGP, GST-pi, Topo-II and LRP in malignant tissues (49.2%, 75.4%, 68.1% and 58%, respectively) were all higher than that of the normal tissues(0, 30%, 20% and 0, respectively, P < 0.01).
  • GST-pi expression status progressively increased with increasing differentiated degree (40%, 75.8% and 88.5%, P < 0.05) and clinicopathologic stage (staging 1/2 vs 3/4, 57.1% vs 83.3%, P < 0.05).
  • The expression of Topo-II was associated with increasing differentiated degree (33.3%, 69.7 and 80.7%, P < 0.01).
  • No significant differences with Topo-II expression were found in relation to the clinicopathologic stage (staging 1/2 vs 3/4, 57.1% vs 72.9%, P > 0.05) and lymphatic metastasis (with vs. without metastasis, 65.0% vs 72.4%, P > 0.05).
  • Moreover, a significant difference with the expression of LRP was found in relation to the clinicopathologic stage (staging 1/2 vs 3/4, 38% vs 66.6%, P < 0.05), and lymphatic metastasis (with vs without metastasis, 70.0% vs 41.4%, P < 0.05).
  • The positive rates of co-expression of PGP and GST-pi, PGP and Topo-II, PGP and LRP, GST-pi and Topo-II, LRP and GST-pi, LRP and Topo-II, PGP, GST-pi, Topo-II and LRP in malignant cells were 23.2%, 15.9%, 11.6%, 13.0, 26.1, 7.24, 5.8, respectively.
  • CONCLUSIONS: MDR-related proteins PGP, GST-pi, Topo-II alpha and LRP are involved in multiple mechanisms of drug resistance in PGCA.
  • Combined determination of PGP, GST-pi, Topo-II and LRP may be prospectively valuable for optimizing the chemotherapy regimes, developing high quality anti-cancer drugs, and further predicting the outcomes of those patients with PGCA.
  • [MeSH-major] Adenocarcinoma / chemistry. Cardia / chemistry. DNA Topoisomerases, Type II / analysis. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Glutathione S-Transferase pi / analysis. Neoplasm Proteins / analysis. P-Glycoprotein / analysis. Stomach Neoplasms / chemistry. Vault Ribonucleoprotein Particles / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443954.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


92. Sakurai H, Asamura H, Goya T, Eguchi K, Nakanishi Y, Sawabata N, Okumura M, Miyaoka E, Fujii Y, Japanese Joint Committee for Lung Cancer Registration: Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study. J Thorac Oncol; 2010 Oct;5(10):1594-601
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study.
  • INTRODUCTION: Women with non-small cell lung cancer (NSCLC) are more likely to have better survival than men.
  • METHODS: In 2005, the Japanese Joint Committee for Lung Cancer Registration performed a nationwide retrospective registry study regarding the prognosis and clinicopathologic profiles of patients who underwent resection for primary lung neoplasms in 1999.
  • Women had a higher incidence of adenocarcinoma (p < 0.001) and stage IA disease (p < 0.001) than men.
  • According to histology, the overall survival of women was significantly better than that of men for both adenocarcinoma (5-YSR, 77.7 versus 61.9%, p = 0.0000) and nonadenocarcinoma (5-YSR, 59.3 versus 53.1%, p = 0.035).
  • In adenocarcinoma, women had a significantly better prognosis than men for pathologic stage I/II disease.
  • However, in nonadenocarcinoma, there was no significant prognostic difference between the two genders in pathologic stage I/II disease.
  • CONCLUSIONS: Women with NSCLC, especially with an adenocarcinoma histology, had better survival than men.
  • Women were more likely to have adenocarcinoma and stage IA disease, which might account for the better prognosis in women.
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Large Cell / mortality. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Squamous Cell / mortality. Lung Neoplasms / mortality


93. Hirsh V, Soulieres D, Duclos M, Faria S, Del Vecchio P, Ofiara L, Ayoub JP, Charpentier D, Gruber J, Portelance L, Souhami L: Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer. J Thorac Oncol; 2007 Oct;2(10):927-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
  • INTRODUCTION: The optimal combination of concomitant radiotherapy (RT) and chemotherapy in stage III unresectable non-small cell lung cancer (NSCLC) remains unclear.
  • The role of induction chemotherapy with carboplatin/gemcitabine regimen has not been established in stage III NSCLC.
  • METHODS: Forty-two stage III NSCLC patients, 41 assessable, with a median age of 60 years and good performance status, entered this trial between January 2003 and November 2004.
  • The median survival was 25 months, the 1-year survival rate was 73.2%, and the 2-year survival rate was 50.5%.
  • Further studies using this approach are warranted in patients with stage III NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Carboplatin / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dose-Response Relationship, Drug. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Prospective Studies. Radiotherapy Dosage. Remission Induction. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909355.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


94. Rusu P, Ciuleanu TE, Cernea D, Pelau D, Gaal V, Cebotaru C, Guttman T, Todor N, Ghilezan N: Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study. J BUON; 2007 Jan-Mar;12(1):33-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
  • PURPOSE: To determine the efficacy, toxicity and survival of concurrent therapy with vinorelbine and a platinum compound with radiotherapy (RT), followed by consolidation chemotherapy with the same drugs, for locally advanced non small cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: Fifty-seven patients with stage III NSCLC were included in this phase II study: median age 56 years (range 44-71), males / females 49/8, ECOG performance status (PS) 1/2=27/30, stage IIIA/ IIIB 11/46, squamous cell carcinoma 44, adenocarcinoma 7, adenoid cystic carcinoma 1 and large cell carcinoma 5.
  • Treatment consisted of 2 cycles of chemotherapy with vinorelbine and cisplatin or carboplatin, given concurrently with RT, followed by 2-4 more cycles of consolidation chemotherapy with the same drugs.
  • CONCLUSION: Preliminary analysis indicates that concurrent vinorelbine and a platinum compound with RT followed by consolidation chemotherapy with the same drugs for advanced stage III NSCLC is well tolerated, has considerable activity and positive impact on survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17436399.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Radiation-Protective Agents; 5V9KLZ54CY / Vinblastine; BG3F62OND5 / Carboplatin; M487QF2F4V / Amifostine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


95. Han PH, Li XJ, Qin H, Yao J, DU N, Ren H: [Upregulation of survivin in non-small cell lung cancer and its clinicopathological correlation with p53 and Bcl-2]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Aug;25(8):710-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Upregulation of survivin in non-small cell lung cancer and its clinicopathological correlation with p53 and Bcl-2].
  • AIM: To retrospectively analyze the clinicopathological data of 87 non-small cell lung cancer (NSCLC) specimens and explore the clinicopathological correlation of survivin with p53 and Bcl-2 and the applicability of combined detection for NSCLC prognosis.
  • NSCLC at various stages showed significant difference in the positivity of survivin: at stage III and IV (mid and late stage) was 71.1% (32/45) while at stage I and II (early and mid stage) was 38.1% (16/42, P<0.01).
  • Survivin was detected in 76.0% (38/50) squamous cell carcinoma and 27.0% (10/37) of adenocarcinoma in a significantly different manner (P<0.01).
  • Moreover, p53 expression was tissue-specific whereby the positivity with squamous cell carcinoma (76.0%, 38/50) was significantly higher than that with adenocarcinoma (27.0%), (10/37, P<0.01).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / pathology. Gene Expression Regulation, Neoplastic. Microtubule-Associated Proteins / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism. Up-Regulation

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664395.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


96. Elayadi AN, Samli KN, Prudkin L, Liu YH, Bian A, Xie XJ, Wistuba II, Roth JA, McGuire MJ, Brown KC: A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res; 2007 Jun 15;67(12):5889-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer.
  • The development of new modes of diagnosis and targeted therapy for lung cancer is dependent on the identification of unique cell surface features on cancer cells and isolation of reagents that bind with high affinity and specificity to these biomarkers.
  • We recently isolated a 20-mer peptide which binds to the lung adenocarcinoma cell line, H2009, from a phage-displayed peptide library.
  • We show here that the cellular receptor for this peptide, TP H2009.1, is the uniquely expressed integrin, alphavbeta6, and the peptide binding to lung cancer cell lines correlates to integrin expression.
  • Expression of alphavbeta6 was assessed on 311 human lung cancer samples.
  • The expression of this integrin is widespread in early-stage nonsmall cell lung carcinoma (NSCLC).
  • Preferential expression is observed in the tumors compared with the surrounding normal lung tissue.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575158.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HV / N01-HV-28185; United States / NCI NIH HHS / CA / P50CA70907; United States / NCI NIH HHS / CA / R01 CA106646; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / 1 R01 CA 106646-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Integrins; 0 / Peptide Library; 0 / Peptides; 0 / integrin alphavbeta6
  •  go-up   go-down


97. Kim AW, Faber LP, Warren WH, Shah ND, Basu S, Liptay MJ: Bilobectomy for non-small cell lung cancer: a search for clinical factors that may affect perioperative morbidity and long-term survival. J Thorac Cardiovasc Surg; 2010 Mar;139(3):606-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilobectomy for non-small cell lung cancer: a search for clinical factors that may affect perioperative morbidity and long-term survival.
  • OBJECTIVE: The resection of two lobes for non-small cell lung cancer has the potential for significant morbidity and mortality as well as a negative impact on survival.
  • METHODS: Age, gender, diagnosis, bilobectomy type, bilobectomy indication, operative technique, pathologic condition, major complications, stage, and survival were reviewed from 1984 through 2007.
  • RESULTS: Bilobectomies were performed on 92 patients with non-small cell lung cancer.
  • Significant differences in survival were observed among the different stages (stage I, 65%; stage II, 42%; stage III, 13%; P < .0001).
  • When bilobectomy was performed for extension across the fissure, survival approached significance for squamous cell carcinomas (71%) over adenocarcinomas (42%) by log-rank test (P < .089) and was significant by likelihood ratio (P < .048) when comparing survival between adenocarcinoma and squamous cell carcinoma.
  • Multivariate analysis demonstrated that increasing age (P = .0102) and upper&middle bilobectomy (P = .0285) adversely affected 5-year survival, whereas early-stage disease (P = .0245) beneficially affected 5-year survival.
  • Survival relates to disease stage.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / mortality. Lung Neoplasms / surgery. Pneumonectomy / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 The American Association for Thoracic Surgery. All rights reserved.
  • (PMID = 19709677.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Cicenas S, Vencevicius V: Lung cancer in patients with tuberculosis. World J Surg Oncol; 2007;5:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer in patients with tuberculosis.
  • BACKGROUND: Coexistent lung cancer and pulmonary tuberculosis is an urgent problem of thoracic surgery presenting a challenging task for diagnosis and surgical treatment.
  • MATERIALS AND METHODS: From 1990 to 2005, 2218 patients with lung cancer underwent surgical treatment in Department of Thoracic Surgery and Oncology, Institute of Oncology, Vilnius University.
  • In 46 (2.1%) patients coexistence of lung cancer and tuberculosis was found.
  • Central lung cancer was diagnosed in 37 (80.4%) and peripheral--in 9 (19.6%) patients.
  • Epidermoid cancer was diagnosed in 24 (52.2%) patients, adenocarcinoma--in 10 (21.7%) and adenoepidermoid carcinoma--in 12 (26.1%) patients.
  • Stage I cancer was diagnosed in 12 (26.1%), stage II--in 11 (23.9%), and stage IIIA--in 23 (50%) patients.
  • CONCLUSION: Coexistence of tuberculosis and lung cancer in thoracic surgery is fairly rare.
  • This combination was diagnosed only in 46 cases (2.1%) out of 2218 operated lung cancer patients.
  • Epidermoid carcinoma and stage IIIA disease was diagnosed in 50% of patients.
  • Postoperative surgical complications occurred in 9 patients (19.5%) with lung cancer and tuberculosis.
  • Surgery is the method of choice in treatment of combination of tuberculosis and lung cancer.
  • [MeSH-major] Lung Neoplasms / epidemiology. Lung Neoplasms / therapy. Pneumonectomy / methods. Tuberculosis, Pulmonary / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kekkaku. 1999 Feb;74(2):157-62 [10191612.001]
  • [Cites] Probl Tuberk. 1984 Aug;(8):55-8 [6238330.001]
  • [Cites] Arkh Patol. 1986;48(3):52-60 [3010915.001]
  • [Cites] Probl Tuberk. 1989;(6):26-9? [2771907.001]
  • [Cites] J Postgrad Med. 1991 Oct;37(4):185-9 [1841965.001]
  • [Cites] Jpn J Clin Oncol. 1993 Aug;23(4):205-20 [8411734.001]
  • [Cites] Chest. 1994 Feb;105(2):514-9 [7905815.001]
  • [Cites] Kekkaku. 1999 Nov;74(11):797-802 [10599212.001]
  • [Cites] Am J Epidemiol. 1995 Jun 1;141(11):1023-32 [7771438.001]
  • (PMID = 17309797.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1805441
  • [General-notes] NLM/ Original DateCompleted: 20070810
  •  go-up   go-down


99. Xiong JP, Feng M, Qiu F, Xu J, Tao QS, Zhang L, Xiang XJ, Zhong LX, Yu F, Ma XT, Gong WY: Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Lung Cancer; 2008 May;60(2):208-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer.
  • PURPOSE: To evaluate the efficacy and safety of the combination of gemcitabine at a low dose of 250 mg/m(2) in 6h prolonged infusion with cisplatin in chemonaive patients with advanced non-small cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: Fifty-eight chemonaive patients with stage IIIB or IV NSCLC were included, 39 males and 19 females, with a median age 61 years (range 28-73).
  • Thirty-four (58.6%) patients had adenocarcinoma, 18 (31.0%) squamous cell, and 6 (10.4%) others.
  • Seventeen (29.3%) had stage IIIB and 41 (70.7%) stage IV.
  • Treatment consisted of 250 mg/m(2) gemcitabine in a 6h infusion on days 1 and 8, and cisplatin at 75 mg/m(2) on day 2 of a 3-week cycle.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / antagonists & inhibitors. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy


100. Oxnard GR, Fidias P, Muzikansky A, Sequist LV: Non-small cell lung cancer in octogenarians: treatment practices and preferences. J Thorac Oncol; 2007 Nov;2(11):1029-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-small cell lung cancer in octogenarians: treatment practices and preferences.
  • INTRODUCTION: Among patients with non-small cell lung cancer (NSCLC), patients aged 80 or older have inferior survival.
  • Patient treatment regimens were evaluated for consistency with contemporaneous stage-specific guideline-recommended therapy (GRT).
  • RESULTS: Patients characteristics included median age of 82.6 years (range, 80-92), 30% stage I-II, 39% stage IV, 59% performance status 0-1, 25% performance status >or=2 (performance status unavailable for 15%).
  • Of 70 patients with stage III or IV disease, 36% received cytotoxic chemotherapy and 27% received oral targeted therapy alone.
  • Thirty-two percent of patients received the stage-specific GRT.
  • CONCLUSIONS: The vast majority of octogenarian patients with NSCLC receive antineoplastic therapy, but only one third of this population receives stage-specific GRT.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / therapy. Age Distribution. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / therapy. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17975495.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement